| Symbol | MRNA |
|---|---|
| Name | MODERNA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 325 BINNEY STREET, CAMBRIDGE, Massachusetts, 02142, United States |
| Telephone | +1 617 - 714-6500 |
| Fax | — |
| — | |
| Website | https://www.modernatx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001682852 |
| Description | Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firms mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. Additional info from NASDAQ: |
2026-06-08 20:34
Klinger Shannon Thyme 🟡 adjusted position in 9.2K shares (2 derivative) of Moderna, Inc. (MRNA) at $51.59 Transaction Date: Jun 04, 2026 | Filing ID: 000119
Read more
2026-06-08 20:30
Mock James M 🟡 adjusted position in 5.7K shares (1 derivative) of Moderna, Inc. (MRNA) at $51.59 Transaction Date: Jun 05, 2026 | Filing ID: 000117
Read more
2026-06-04 17:26
📋 Klinger Shannon Thyme (Officer) plans to sell 3K shares of Moderna, Inc. (at $50.00 each, total $174K) Filed: Jun 04, 2026 | ID: 004339
Read more
2026-06-03 20:21
Mock James M 🟡 adjusted position in 1.2K shares (1 derivative) of Moderna, Inc. (MRNA) at $47.19 Transaction Date: Jun 01, 2026 | Filing ID: 000115
Read more
2026-06-03 20:19
Klinger Shannon Thyme 🟡 adjusted position in 1.0K shares (1 derivative) of Moderna, Inc. (MRNA) at $47.19 Transaction Date: Jun 01, 2026 | Filing ID: 000113
Read more
2026-06-03 20:16
Hoge Stephen 🟡 adjusted position in 4.5K shares (1 derivative) of Moderna, Inc. (MRNA) at $47.19 Transaction Date: Jun 01, 2026 | Filing ID: 000111
Read more
2026-05-29 21:13
Mock James M 🟡 adjusted position in 533 shares (2 derivative) of Moderna, Inc. (MRNA) at $47.61 Transaction Date: May 27, 2026 | Filing ID: 000109
Read more
2026-05-29 21:10
Klinger Shannon Thyme 🟡 adjusted position in 533 shares (2 derivative) of Moderna, Inc. (MRNA) at $47.61 Transaction Date: May 27, 2026 | Filing ID: 000107
Read more
2026-05-29 21:04
Hoge Stephen 🟡 adjusted position in 990 shares (2 derivative) of Moderna, Inc. (MRNA) at $47.61 Transaction Date: May 27, 2026 | Filing ID: 000105
Read more
2026-05-22 23:00
AFEYAN NOUBAR 🟡 adjusted position in 9.3K shares (1 derivative) of Moderna, Inc. (MRNA) at $46.84 Transaction Date: May 21, 2026 | Filing ID: 237309
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07561294 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982… | Phase2 | Lyme Disease | Recruiting | 2026-04-29 | 2028-11-09 | ClinicalTrials.gov |
| NCT07496450 | A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults | Phase3 | Influenza | Recruiting | 2026-03-23 | 2027-01-28 | ClinicalTrials.gov |
| NCT07478952 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy … | Phase1 | Epstein-Barr Virus | Recruiting | 2026-03-17 | 2027-05-15 | ClinicalTrials.gov |
| NCT06694753 | Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult… | Phase1 | HIV Infections | Recruiting | 2025-12-15 | 2027-03-31 | ClinicalTrials.gov |
| NCT07279766 | Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Sever… | Phase4 | COVID-19 | Active_Not_Recruiting | 2025-12-11 | 2026-08-01 | ClinicalTrials.gov |
| NCT07266558 | A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Parti… | Phase4 | SARS-CoV-2 | Active_Not_Recruiting | 2025-11-26 | 2027-06-16 | ClinicalTrials.gov |
| NCT07116616 | A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myelo… | Phase1 | Relapsed or Refractory Multiple Myeloma | Recruiting | 2025-09-30 | 2032-06-17 | ClinicalTrials.gov |
| NCT07117487 | A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Res… | Phase3 | Respiratory Syncytial Virus | Completed | 2025-08-05 | 2026-03-27 | ClinicalTrials.gov |
| NCT06946225 | ACTengine® IMA203 Combined With mRNA-4203 | Phase1 | Cutaneous Melanoma | Recruiting | 2025-07-25 | 2029-08-01 | ClinicalTrials.gov |
| NCT07089706 | A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant… | Phase4 | COVID-19 | Recruiting | 2025-07-21 | 2026-06-19 | ClinicalTrials.gov |
| NCT06735248 | A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Com… | Phase2 | Multiple Sclerosis | Recruiting | 2025-04-16 | 2029-01-08 | ClinicalTrials.gov |
| NCT06880549 | A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Ant… | Phase1 | Advanced Solid Tumors | Active_Not_Recruiting | 2025-03-25 | 2027-08-03 | ClinicalTrials.gov |
| NCT06864143 | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1… | Phase2 | Influenza | Completed | 2025-03-07 | 2025-10-13 | ClinicalTrials.gov |
| NCT06694389 | Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-108… | Phase3 | COVID-19 | Completed | 2024-11-18 | 2025-11-17 | ClinicalTrials.gov |
| NCT06655870 | A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcut… | Phase1 | Healthy Participants | Active_Not_Recruiting | 2024-10-31 | 2026-06-23 | ClinicalTrials.gov |
| NCT06646406 | Evaluation of a Multilevel Intervention on Adult COVID-19 and Influenza Vaccina… | Na | COVID-19 Immunisation | Completed | 2024-10-21 | 2025-04-30 | ClinicalTrials.gov |
| NCT06634797 | A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in P… | Phase4 | Healthy Volunteers | Completed | 2024-10-08 | 2025-01-20 | ClinicalTrials.gov |
| NCT06592794 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18… | Phase3 | Acute Gastroenteritis | Active_Not_Recruiting | 2024-09-24 | 2027-02-15 | ClinicalTrials.gov |
| NCT06602024 | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Y… | Phase3 | Seasonal Influenza | Completed | 2024-09-16 | 2025-08-21 | ClinicalTrials.gov |
| NCT06585241 | A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-c… | Phase4 | SARS-CoV-2 | Recruiting | 2024-09-09 | 2026-12-31 | ClinicalTrials.gov |
| NCT06508320 | A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Pr… | Phase2 | Influenza | Completed | 2024-07-15 | 2025-09-25 | ClinicalTrials.gov |
| NCT06295809 | A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutane… | Phase2 | Carcinoma, Squamous Cell | Terminated | 2024-04-18 | 2026-03-05 | ClinicalTrials.gov |
| NCT06307431 | A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell … | Phase2 | Renal Cell Carcinoma | Active_Not_Recruiting | 2024-04-10 | 2032-06-08 | ClinicalTrials.gov |
| NCT06354998 | A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vacc… | Phase3 | SARS-CoV-2 | Completed | 2024-04-08 | 2024-05-10 | ClinicalTrials.gov |
| NCT06147856 | A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria | Phase1 | Phenylketonuria | Withdrawn | 2024-03-29 | 2027-08-05 | ClinicalTrials.gov |
| NCT06305767 | A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in P… | Phase1 | Bladder Cancer | Active_Not_Recruiting | 2024-03-28 | 2031-10-20 | ClinicalTrials.gov |
| NCT06243770 | Study to Investigate Safety and Tolerability of mRNA-0184 Administered Under Di… | Phase1 | Healthy Participants | Completed | 2024-02-16 | 2025-06-12 | ClinicalTrials.gov |
| NCT06133010 | A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and… | Phase2 | Cytomegalovirus Infection | Withdrawn | 2024-02-08 | 2027-12-14 | ClinicalTrials.gov |
| NCT05831787 | COVID19 OutcomeS in Myeloma and the Impact of VaCcines | — | Multiple Myeloma | Completed | 2024-01-23 | 2024-12-31 | ClinicalTrials.gov |
| NCT06143046 | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant … | Phase2 | Respiratory Syncytial Virus | Active_Not_Recruiting | 2023-11-15 | 2026-05-27 | ClinicalTrials.gov |
| NCT06097299 | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in… | Phase2 | Respiratory Syncytial Virus | Completed | 2023-10-24 | 2025-06-27 | ClinicalTrials.gov |
| NCT06097273 | A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Partic… | Phase3 | SARS-CoV-2 | Completed | 2023-10-19 | 2024-05-28 | ClinicalTrials.gov |
| NCT06067230 | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targe… | Phase3 | Respiratory Syncytial Virus | Active_Not_Recruiting | 2023-10-06 | 2026-07-30 | ClinicalTrials.gov |
| NCT06060457 | A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targ… | Phase3 | Respiratory Syncytial Virus | Completed | 2023-09-25 | 2024-06-07 | ClinicalTrials.gov |
| NCT06033261 | A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate V… | Phase1 | Genital Herpes | Completed | 2023-09-06 | 2025-04-25 | ClinicalTrials.gov |
| NCT05992935 | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 a… | Phase1 | Norovirus Acute Gastroenteritis | Active_Not_Recruiting | 2023-08-25 | 2026-09-22 | ClinicalTrials.gov |
| NCT05995275 | A Study to Investigate The Safety, Tolerability, And Immune Response of a Range… | Phase1 | Smallpox | Completed | 2023-08-15 | 2025-07-08 | ClinicalTrials.gov |
| NCT05918250 | mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | Phase1 | Relapsed or Refractory Multiple Myeloma | Withdrawn | 2023-08-15 | 2026-05-27 | ClinicalTrials.gov |
| NCT06522880 | Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study | — | Cytomegalovirus Infections | Recruiting | 2023-08-10 | 2027-12-31 | ClinicalTrials.gov |
| NCT05975099 | A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Ag… | Phase1 | Lyme Disease | Completed | 2023-07-26 | 2025-05-30 | ClinicalTrials.gov |
| NCT05933577 | A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People Wit… | Phase3 | Melanoma | Active_Not_Recruiting | 2023-07-19 | 2030-09-26 | ClinicalTrials.gov |
| NCT05972174 | A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults | Phase1 | Influenza | Completed | 2023-07-10 | 2024-07-16 | ClinicalTrials.gov |
| NCT05769621 | A Retrospective Study to Characterize Participants With Propionic Acidemia | — | Propionic Acidemia | Recruiting | 2023-06-16 | 2026-09-30 | ClinicalTrials.gov |
| NCT05868382 | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccin… | Phase2 | Influenza | Completed | 2023-05-15 | 2023-12-19 | ClinicalTrials.gov |
| NCT05827978 | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | Phase3 | Seasonal Influenza | Completed | 2023-04-17 | 2024-06-24 | ClinicalTrials.gov |
| NCT05827926 | A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vacci… | Phase1 | SARS-CoV-2 | Completed | 2023-04-14 | 2024-12-03 | ClinicalTrials.gov |
| NCT06130345 | Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran | — | SARS-CoV-2 | Completed | 2023-04-14 | 2024-08-31 | ClinicalTrials.gov |
| NCT05683457 | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytom… | Phase2 | Cytomegalovirus Infection | Active_Not_Recruiting | 2023-04-05 | 2026-08-01 | ClinicalTrials.gov |
| NCT05831111 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to … | Phase1 | Epstein-Barr Virus Infection | Active_Not_Recruiting | 2023-04-05 | 2026-10-07 | ClinicalTrials.gov |
| NCT06113692 | A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pe… | — | Myocarditis, Pericarditis | Completed | 2023-03-31 | 2025-06-30 | ClinicalTrials.gov |
| NCT05815498 | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participant… | Phase3 | COVID-19 | Completed | 2023-03-28 | 2025-04-12 | ClinicalTrials.gov |
| NCT05827068 | A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influen… | Phase1 | Seasonal Influenza | Completed | 2023-03-27 | 2023-11-20 | ClinicalTrials.gov |
| NCT06333704 | Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALEN… | — | SARS-CoV-2 | Active_Not_Recruiting | 2023-03-10 | 2029-03-29 | ClinicalTrials.gov |
| NCT05765578 | An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omic… | — | COVID-19 | Completed | 2023-03-08 | 2024-06-17 | ClinicalTrials.gov |
| NCT06369272 | Study to Assess Maternal and Infant Outcomes Following Exposure to SPIKEVAX Dur… | — | Maternal Outcomes | Completed | 2023-03-01 | 2023-10-20 | ClinicalTrials.gov |
| NCT05743881 | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in … | Phase1 | Respiratory Syncytial Virus | Active_Not_Recruiting | 2023-02-15 | 2026-09-30 | ClinicalTrials.gov |
| NCT05701800 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468… | Phase1 | Herpes Zoster | Active_Not_Recruiting | 2023-01-23 | 2026-06-30 | ClinicalTrials.gov |
| NCT05794412 | Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observation… | — | SARS-CoV-2 Infection | Completed | 2023-01-10 | 2024-12-31 | ClinicalTrials.gov |
| NCT05659264 | A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure | Phase1 | Chronic Heart Failure | Completed | 2022-12-05 | 2024-12-17 | ClinicalTrials.gov |
| NCT05894499 | Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acut… | — | SARS-CoV-2 | Completed | 2022-11-15 | 2023-05-26 | ClinicalTrials.gov |
| NCT05894525 | Post-Marketing Safety Study in Japan in Participants With High Risk of Severe E… | — | SARS-CoV-2 | Completed | 2022-11-15 | 2023-05-26 | ClinicalTrials.gov |
| NCT05894590 | Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory S… | — | SARS-CoV-2 | Completed | 2022-11-15 | 2023-12-20 | ClinicalTrials.gov |
| NCT05575492 | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Ye… | Phase1 | Cytomegalovirus | Completed | 2022-11-07 | 2026-05-12 | ClinicalTrials.gov |
| NCT05606965 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010… | Phase2 | Influenza | Completed | 2022-11-02 | 2025-11-13 | ClinicalTrials.gov |
| NCT05585632 | A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and … | Phase1 | SARS-CoV-2 | Completed | 2022-10-14 | 2024-02-28 | ClinicalTrials.gov |
| NCT05584202 | Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.21… | Phase2 | SARS-CoV-2 | Terminated | 2022-09-30 | 2024-11-15 | ClinicalTrials.gov |
| NCT05572658 | Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study | — | Respiratory Syncytial Virus | Completed | 2022-09-15 | 2023-09-30 | ClinicalTrials.gov |
| NCT05566639 | A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older | Phase3 | Seasonal Influenza | Completed | 2022-09-14 | 2024-01-05 | ClinicalTrials.gov |
| NCT05383560 | Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults | Phase2 | COVID-19 Pandemic | Completed | 2022-09-05 | 2024-01-31 | ClinicalTrials.gov |
| NCT05533697 | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint… | Phase1 | Advanced Solid Tumors | Recruiting | 2022-09-01 | 2032-02-18 | ClinicalTrials.gov |
| NCT05398796 | Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and… | Phase1 | Nipah Virus Infection | Completed | 2022-07-11 | 2024-09-17 | ClinicalTrials.gov |
| NCT05436834 | A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines… | Phase3 | SARS-CoV-2 | Completed | 2022-06-21 | 2025-10-20 | ClinicalTrials.gov |
| NCT05440318 | Use of Wearable Digital Sensors After mRNA Vaccination in Adults | — | Healthy Participants | Completed | 2022-06-16 | 2023-02-07 | ClinicalTrials.gov |
| NCT05415462 | A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | Phase3 | Seasonal Influenza | Completed | 2022-06-06 | 2023-09-04 | ClinicalTrials.gov |
| NCT05095727 | A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage … | Phase1 | Glycogen Storage Disease | Active_Not_Recruiting | 2022-06-01 | 2026-11-30 | ClinicalTrials.gov |
| NCT05414786 | A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine… | Phase1 | HIV-1-infection | Unknown | 2022-05-25 | 2023-06-30 | ClinicalTrials.gov |
| NCT05397223 | A Study of Modified mRNA Vaccines in Healthy Adults | Phase1 | SARS-CoV-2 | Completed | 2022-05-24 | 2026-02-27 | ClinicalTrials.gov |
| NCT05375838 | A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influ… | Phase1 | SARS-CoV-2 | Completed | 2022-05-13 | 2022-12-29 | ClinicalTrials.gov |
| NCT06189053 | A Study to Assess Long-term Outcomes of Myocarditis Following Administration of… | — | Myocarditis | Active_Not_Recruiting | 2022-04-30 | 2028-10-31 | ClinicalTrials.gov |
| NCT05367908 | A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any K… | — | SARS-CoV-2 | Completed | 2022-04-11 | 2022-08-14 | ClinicalTrials.gov |
| NCT05333289 | A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults | Phase1 | Seasonal Influenza | Completed | 2022-04-06 | 2022-11-22 | ClinicalTrials.gov |
| NCT05330975 | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adu… | Phase3 | Respiratory Syncytial Virus | Completed | 2022-04-01 | 2024-11-08 | ClinicalTrials.gov |
| NCT05280158 | High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients | Phase1 | Lung Transplant Recipient | Terminated | 2022-03-10 | 2023-02-27 | ClinicalTrials.gov |
| NCT05295433 | An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mR… | Phase1 | Methylmalonic Acidemia | Recruiting | 2022-03-08 | 2034-04-02 | ClinicalTrials.gov |
| NCT05249829 | A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines i… | Phase2 | SARS-CoV-2 | Completed | 2022-02-16 | 2023-06-23 | ClinicalTrials.gov |
| NCT05164094 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to … | Phase1 | Epstein-Barr Virus Infection | Active_Not_Recruiting | 2021-12-28 | 2027-08-18 | ClinicalTrials.gov |
| NCT04941144 | Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination | — | Coronavirus Disease (COVID-19) | Completed | 2021-12-22 | 2023-04-28 | ClinicalTrials.gov |
| NCT05137236 | A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine… | Phase2 | SARS-CoV-2 | Completed | 2021-12-06 | 2023-03-23 | ClinicalTrials.gov |
| NCT05127434 | A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Resp… | Phase2 | Respiratory Syncytial Virus | Completed | 2021-11-17 | 2025-07-28 | ClinicalTrials.gov |
| NCT05001373 | A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA… | Phase1 | Hiv | Active_Not_Recruiting | 2021-11-12 | 2024-07-01 | ClinicalTrials.gov |
| NCT05130437 | A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Pa… | Phase1 | Propionic Acidemia | Recruiting | 2021-11-09 | 2031-12-04 | ClinicalTrials.gov |
| NCT05105048 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegal… | Phase1 | Cytomegalovirus Infection | Completed | 2021-11-08 | 2023-08-10 | ClinicalTrials.gov |
| NCT05085366 | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytom… | Phase3 | Cytomegalovirus Infection | Terminated | 2021-10-26 | 2025-11-04 | ClinicalTrials.gov |
| NCT05366322 | A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocomp… | — | SARS-CoV-2 | Completed | 2021-09-10 | 2022-03-21 | ClinicalTrials.gov |
| NCT05054218 | COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patie… | — | Covid19 | Completed | 2021-09-10 | 2022-08-29 | ClinicalTrials.gov |
| NCT04958304 | Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study | — | SARS-CoV-2 | Terminated | 2021-09-01 | 2023-09-22 | ClinicalTrials.gov |
| NCT04899310 | A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-37… | Phase1 | Methylmalonic Acidemia | Terminated | 2021-08-06 | 2026-04-01 | ClinicalTrials.gov |
| NCT04916431 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyn… | Phase1 | Healthy Volunteers | Completed | 2021-07-28 | 2022-08-02 | ClinicalTrials.gov |
| NCT04958954 | Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 … | — | SARS-CoV-2 | Completed | 2021-07-07 | 2023-06-30 | ClinicalTrials.gov |
| NCT04956575 | A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults | Phase1 | Seasonal Influenza | Completed | 2021-07-06 | 2022-09-27 | ClinicalTrials.gov |
| NCT04975893 | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytome… | Phase2 | Cytomegalovirus Infection | Completed | 2021-06-18 | 2026-01-19 | ClinicalTrials.gov |
| NCT04917861 | A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and N… | Phase2 | Zika Virus | Completed | 2021-06-07 | 2024-07-26 | ClinicalTrials.gov |
| NCT04927065 | A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for … | Phase2 | SARS-CoV-2 | Completed | 2021-05-28 | 2023-11-17 | ClinicalTrials.gov |
| NCT04805125 | Immunocompromised Swiss Cohorts Based Trial Platform | Phase3 | Immunocompromised Patients | Completed | 2021-04-19 | 2023-09-23 | ClinicalTrials.gov |
| NCT04860297 | A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent C… | Phase3 | SARS-CoV-2 | Completed | 2021-04-16 | 2023-05-22 | ClinicalTrials.gov |
| NCT04159103 | Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia | Phase1 | Propionic Acidemia | Recruiting | 2021-04-15 | 2027-08-31 | ClinicalTrials.gov |
| NCT04785144 | Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRN… | Phase1 | COVID-19 | Completed | 2021-03-31 | 2022-07-05 | ClinicalTrials.gov |
| NCT04796896 | A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in H… | Phase2 | SARS-CoV-2 | Completed | 2021-03-15 | 2024-03-15 | ClinicalTrials.gov |
| NCT04813796 | A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and… | Phase1 | SARS-CoV-2 | Completed | 2021-03-11 | 2023-07-25 | ClinicalTrials.gov |
| NCT05933304 | A Study of the Effectiveness of Moderna COVID-19 Vaccine | — | SARS-CoV-2 | Completed | 2020-12-18 | 2023-11-17 | ClinicalTrials.gov |
| NCT04649151 | A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 … | Phase2 | SARS-CoV-2 | Completed | 2020-12-09 | 2024-06-14 | ClinicalTrials.gov |
| NCT04528719 | A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity … | Phase1 | Respiratory Syncytial Virus | Completed | 2020-09-30 | 2024-07-18 | ClinicalTrials.gov |
| NCT04470427 | A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine i… | Phase3 | SARS-CoV-2 | Completed | 2020-07-27 | 2022-12-29 | ClinicalTrials.gov |
| NCT04405076 | Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenic… | Phase2 | SARS-CoV-2 | Completed | 2020-05-29 | 2021-10-28 | ClinicalTrials.gov |
| NCT04283461 | Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxi… | Phase1 | COVID-19 | Completed | 2020-03-16 | 2022-04-26 | ClinicalTrials.gov |
| NCT04232280 | Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus… | Phase2 | Cytomegalovirus Infection | Completed | 2020-01-09 | 2023-01-04 | ClinicalTrials.gov |
| NCT04144348 | Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV)… | Phase1 | Human Metapneumovirus and Human Parainfluenza Infection | Completed | 2019-11-04 | 2022-12-20 | ClinicalTrials.gov |
| NCT04064905 | Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy F… | Phase1 | Zika Virus | Completed | 2019-07-30 | 2021-03-22 | ClinicalTrials.gov |
| NCT03897881 | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mR… | Phase2 | Melanoma | Active_Not_Recruiting | 2019-07-18 | 2032-11-30 | ClinicalTrials.gov |
| NCT03948763 | A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab … | Phase1 | Neoplasms | Terminated | 2019-06-26 | 2022-08-25 | ClinicalTrials.gov |
| NCT03810690 | Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia | Phase1 | Methylmalonic Acidemia (MMA) | Withdrawn | 2019-05-28 | 2020-08-18 | ClinicalTrials.gov |
| NCT03829384 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in He… | Phase1 | Prevention of Chikungunya Virus Infection | Completed | 2019-01-22 | 2021-06-07 | ClinicalTrials.gov |
| NCT03739931 | Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants i… | Phase1 | Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma | Completed | 2018-11-27 | 2025-08-01 | ClinicalTrials.gov |
| NCT03484767 | "The MaP Study": Mapping the Patient Journey in MMA and PA | — | Methylmalonic Acidemia | Completed | 2018-03-20 | 2021-05-29 | ClinicalTrials.gov |
| NCT03392389 | Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults | Phase1 | Human Metapneumovirus and Human Parainfluenza Infection | Completed | 2017-12-04 | 2019-07-29 | ClinicalTrials.gov |
| NCT03382405 | Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-164… | Phase1 | Cytomegalovirus Infection | Completed | 2017-11-13 | 2020-10-28 | ClinicalTrials.gov |
| NCT03323398 | Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alon… | Phase1 | Relapsed/Refractory Solid Tumor Malignancies or Lymphoma | Terminated | 2017-08-15 | 2021-08-18 | ClinicalTrials.gov |
| NCT03313778 | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination … | Phase1 | Solid Tumors | Active_Not_Recruiting | 2017-08-14 | 2027-11-21 | ClinicalTrials.gov |
| NCT03325075 | Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants | Phase1 | Chikungunya Virus | Completed | 2017-07-19 | 2019-03-19 | ClinicalTrials.gov |
| NCT03014089 | Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects | Phase1 | Zika Virus | Completed | 2016-12-21 | 2019-07-31 | ClinicalTrials.gov |
| NCT02872025 | Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS) | Early_Phase1 | Carcinoma, Intraductal, Noninfiltrating | Active_Not_Recruiting | 2016-12-12 | 2026-03-31 | ClinicalTrials.gov |
| NCT03345043 | Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects | Phase1 | Influenza | Completed | 2016-05-11 | 2018-08-13 | ClinicalTrials.gov |
| NCT03076385 | Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects | Phase1 | Influenza | Completed | 2015-12-01 | 2018-10-01 | ClinicalTrials.gov |
Total clinical trials: 133
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE1 | Cytomegalovirus | COMPLETED | NCT05575492 |
| mRNA-1647 | Other | Phase PHASE1 | Cytomegalovirus | COMPLETED | NCT05575492 |
| Nivolumab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT05533697 |
| Ipilimumab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT05533697 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT05533697 |
| mRNA-4359 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT05533697 |
| Placebo | Other | Phase PHASE2 | Lyme Disease | RECRUITING | NCT07561294 |
| mRNA-1982 | Other | Phase PHASE2 | Lyme Disease | RECRUITING | NCT07561294 |
| mRNA-4200 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06880549 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06880549 |
| mRNA-4106 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06880549 |
| mRNA-4200 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06880549 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06880549 |
| mRNA-4106 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06880549 |
| mRNA-4200 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06880549 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06880549 |
| mRNA-4106 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06880549 |
| mRNA-4200 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06880549 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06880549 |
| mRNA-4106 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06880549 |
| mRNA-4200 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06880549 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06880549 |
| mRNA-4106 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06880549 |
| mRNA-4200 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06880549 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06880549 |
| mRNA-4106 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06880549 |
| mRNA-4200 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06880549 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06880549 |
| mRNA-4106 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06880549 |
| mRNA-1283.251 Variant-containing Formulation | Other | Phase PHASE4 | COVID-19 | RECRUITING | NCT07089706 |
| mRNA-1283.251 Variant-containing Formulation | Other | Phase PHASE4 | COVID-19 | RECRUITING | NCT07089706 |
| mRNA-1283.251 Variant-containing Formulation | Other | Phase PHASE4 | COVID-19 | RECRUITING | NCT07089706 |
| mRNA-1283.251 Variant-containing Formulation | Other | Phase PHASE4 | COVID-19 | RECRUITING | NCT07089706 |
| mRNA-1283.251 Variant-containing Formulation | Other | Phase PHASE4 | COVID-19 | RECRUITING | NCT07089706 |
| mRNA-1283.251 Variant-containing Formulation | Other | Phase PHASE4 | COVID-19 | RECRUITING | NCT07089706 |
| mRNA-1283.251 Variant-containing Formulation | Other | Phase PHASE4 | COVID-19 | RECRUITING | NCT07089706 |
| mRNA-1283.251 Variant-containing Formulation | Other | Phase PHASE4 | COVID-19 | RECRUITING | NCT07089706 |
| mRNA-1283.251 Variant-containing Formulation | Other | Phase PHASE4 | COVID-19 | RECRUITING | NCT07089706 |
| mRNA-1283.251 Variant-containing Formulation | Other | Phase PHASE4 | COVID-19 | RECRUITING | NCT07089706 |
| mRNA-1283.251 Variant-containing Formulation | Other | Phase PHASE4 | COVID-19 | RECRUITING | NCT07089706 |
| mRNA-1283.251 Variant-containing Formulation | Other | Phase PHASE4 | COVID-19 | RECRUITING | NCT07089706 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-1283.251 Variant-containing Formulation | Other | Phase PHASE4 | COVID-19 | RECRUITING | NCT07089706 |
| mRNA-2808 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | RECRUITING | NCT07116616 |
| Patient Reported Outcomes | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT05831787 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-1283.251 Variant-containing Formulation | Other | Phase PHASE4 | COVID-19 | RECRUITING | NCT07089706 |
| mRNA-2808 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | RECRUITING | NCT07116616 |
| Patient Reported Outcomes | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT05831787 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-1283.251 Variant-containing Formulation | Other | Phase PHASE4 | COVID-19 | RECRUITING | NCT07089706 |
| mRNA-2808 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | RECRUITING | NCT07116616 |
| Patient Reported Outcomes | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT05831787 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-1283.251 Variant-containing Formulation | Other | Phase PHASE4 | COVID-19 | RECRUITING | NCT07089706 |
| mRNA-2808 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | RECRUITING | NCT07116616 |
| Patient Reported Outcomes | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT05831787 |
| mRNA-2808 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | RECRUITING | NCT07116616 |
| Patient Reported Outcomes | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT05831787 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-2808 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | RECRUITING | NCT07116616 |
| Patient Reported Outcomes | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT05831787 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-2808 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | RECRUITING | NCT07116616 |
| Patient Reported Outcomes | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT05831787 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-2808 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | RECRUITING | NCT07116616 |
| Patient Reported Outcomes | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT05831787 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-2808 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | RECRUITING | NCT07116616 |
| Patient Reported Outcomes | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT05831787 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-2808 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | RECRUITING | NCT07116616 |
| Patient Reported Outcomes | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT05831787 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-2808 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | RECRUITING | NCT07116616 |
| Patient Reported Outcomes | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT05831787 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-2808 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | RECRUITING | NCT07116616 |
| Patient Reported Outcomes | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT05831787 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-2808 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | RECRUITING | NCT07116616 |
| Patient Reported Outcomes | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT05831787 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-2808 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | RECRUITING | NCT07116616 |
| Patient Reported Outcomes | Other | Preclinical | Multiple Myeloma | COMPLETED | NCT05831787 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | ACTIVE_NOT_RECRUITING | NCT05683457 |
| Placebo | Other | Phase PHASE3 | Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT06592794 |
| mRNA-1403 | Other | Phase PHASE3 | Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT06592794 |
| Placebo | Other | Phase PHASE3 | Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT06592794 |
| mRNA-1403 | Other | Phase PHASE3 | Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT06592794 |
| Placebo | Other | Phase PHASE3 | Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT06592794 |
| mRNA-1403 | Other | Phase PHASE3 | Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT06592794 |
| Placebo | Other | Phase PHASE3 | Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT06592794 |
| mRNA-1403 | Other | Phase PHASE3 | Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT06592794 |
| Placebo | Other | Phase PHASE3 | Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT06592794 |
| mRNA-1403 | Other | Phase PHASE3 | Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT06592794 |
| Placebo | Other | Phase PHASE3 | Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT06592794 |
| mRNA-1403 | Other | Phase PHASE3 | Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT06592794 |
| Placebo | Other | Phase PHASE2 | Lyme Disease | RECRUITING | NCT07561294 |
| mRNA-1982 | Other | Phase PHASE2 | Lyme Disease | RECRUITING | NCT07561294 |
| mRNA-2808 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | RECRUITING | NCT07116616 |
| Placebo | Other | Phase PHASE2 | Lyme Disease | RECRUITING | NCT07561294 |
| mRNA-1982 | Other | Phase PHASE2 | Lyme Disease | RECRUITING | NCT07561294 |
| mRNA-2808 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | RECRUITING | NCT07116616 |
| Placebo | Other | Phase PHASE2 | Lyme Disease | RECRUITING | NCT07561294 |
| mRNA-1982 | Other | Phase PHASE2 | Lyme Disease | RECRUITING | NCT07561294 |
| mRNA-2808 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | RECRUITING | NCT07116616 |
| Placebo | Other | Phase PHASE2 | Lyme Disease | RECRUITING | NCT07561294 |
| mRNA-1982 | Other | Phase PHASE2 | Lyme Disease | RECRUITING | NCT07561294 |
| mRNA-2808 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | RECRUITING | NCT07116616 |
| Placebo | Other | Phase PHASE2 | Lyme Disease | RECRUITING | NCT07561294 |
| mRNA-1982 | Other | Phase PHASE2 | Lyme Disease | RECRUITING | NCT07561294 |
| mRNA-2808 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | RECRUITING | NCT07116616 |
| Placebo | Other | Phase PHASE2 | Lyme Disease | RECRUITING | NCT07561294 |
| mRNA-1982 | Other | Phase PHASE2 | Lyme Disease | RECRUITING | NCT07561294 |
| mRNA-2808 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | RECRUITING | NCT07116616 |
| BEXSERO | Other | Phase PHASE1 | Genital Herpes | COMPLETED | NCT06033261 |
| mRNA-1608 | Other | Phase PHASE1 | Genital Herpes | COMPLETED | NCT06033261 |
| Surgery | Procedure | Phase PHASE2 | Carcinoma, Squamous Cell | TERMINATED | NCT06295809 |
| Intismeran autogene | Other | Phase PHASE2 | Carcinoma, Squamous Cell | TERMINATED | NCT06295809 |
| Pembrolizumab | Other | Phase PHASE2 | Carcinoma, Squamous Cell | TERMINATED | NCT06295809 |
| BEXSERO | Other | Phase PHASE1 | Genital Herpes | COMPLETED | NCT06033261 |
| mRNA-1608 | Other | Phase PHASE1 | Genital Herpes | COMPLETED | NCT06033261 |
| Surgery | Procedure | Phase PHASE2 | Carcinoma, Squamous Cell | TERMINATED | NCT06295809 |
| Intismeran autogene | Other | Phase PHASE2 | Carcinoma, Squamous Cell | TERMINATED | NCT06295809 |
| Pembrolizumab | Other | Phase PHASE2 | Carcinoma, Squamous Cell | TERMINATED | NCT06295809 |
| BEXSERO | Other | Phase PHASE1 | Genital Herpes | COMPLETED | NCT06033261 |
| mRNA-1608 | Other | Phase PHASE1 | Genital Herpes | COMPLETED | NCT06033261 |
| Surgery | Procedure | Phase PHASE2 | Carcinoma, Squamous Cell | TERMINATED | NCT06295809 |
| Intismeran autogene | Other | Phase PHASE2 | Carcinoma, Squamous Cell | TERMINATED | NCT06295809 |
| Pembrolizumab | Other | Phase PHASE2 | Carcinoma, Squamous Cell | TERMINATED | NCT06295809 |
| Placebo | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-N332GT5 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-CoreG28v2 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-eODGT8 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| BEXSERO | Other | Phase PHASE1 | Genital Herpes | COMPLETED | NCT06033261 |
| mRNA-1608 | Other | Phase PHASE1 | Genital Herpes | COMPLETED | NCT06033261 |
| Surgery | Procedure | Phase PHASE2 | Carcinoma, Squamous Cell | TERMINATED | NCT06295809 |
| Intismeran autogene | Other | Phase PHASE2 | Carcinoma, Squamous Cell | TERMINATED | NCT06295809 |
| Pembrolizumab | Other | Phase PHASE2 | Carcinoma, Squamous Cell | TERMINATED | NCT06295809 |
| Placebo | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-N332GT5 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-CoreG28v2 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-eODGT8 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| Surgery | Procedure | Phase PHASE2 | Carcinoma, Squamous Cell | TERMINATED | NCT06295809 |
| Intismeran autogene | Other | Phase PHASE2 | Carcinoma, Squamous Cell | TERMINATED | NCT06295809 |
| Pembrolizumab | Other | Phase PHASE2 | Carcinoma, Squamous Cell | TERMINATED | NCT06295809 |
| Placebo | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-N332GT5 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-CoreG28v2 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-eODGT8 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| Placebo | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-N332GT5 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-CoreG28v2 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-eODGT8 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| Placebo | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-N332GT5 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-CoreG28v2 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-eODGT8 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| Placebo | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-N332GT5 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-CoreG28v2 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-eODGT8 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| Placebo | Other | Phase PHASE1 | Methylmalonic Acidemia | TERMINATED | NCT04899310 |
| mRNA-3705 | Other | Phase PHASE1 | Methylmalonic Acidemia | TERMINATED | NCT04899310 |
| Placebo | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05164094 |
| mRNA-1189 | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05164094 |
| Placebo | Other | Phase PHASE1 | Methylmalonic Acidemia | TERMINATED | NCT04899310 |
| mRNA-3705 | Other | Phase PHASE1 | Methylmalonic Acidemia | TERMINATED | NCT04899310 |
| Placebo | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05164094 |
| mRNA-1189 | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05164094 |
| Placebo | Other | Phase PHASE1 | Methylmalonic Acidemia | TERMINATED | NCT04899310 |
| mRNA-3705 | Other | Phase PHASE1 | Methylmalonic Acidemia | TERMINATED | NCT04899310 |
| Placebo | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05164094 |
| mRNA-1189 | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05164094 |
| Placebo | Other | Phase PHASE1 | Methylmalonic Acidemia | TERMINATED | NCT04899310 |
| mRNA-3705 | Other | Phase PHASE1 | Methylmalonic Acidemia | TERMINATED | NCT04899310 |
| Placebo | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05164094 |
| mRNA-1189 | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05164094 |
| Placebo | Other | Phase PHASE1 | Methylmalonic Acidemia | TERMINATED | NCT04899310 |
| mRNA-3705 | Other | Phase PHASE1 | Methylmalonic Acidemia | TERMINATED | NCT04899310 |
| Placebo | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05164094 |
| mRNA-1189 | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05164094 |
| Placebo | Other | Phase PHASE1 | Methylmalonic Acidemia | TERMINATED | NCT04899310 |
| mRNA-3705 | Other | Phase PHASE1 | Methylmalonic Acidemia | TERMINATED | NCT04899310 |
| Placebo | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05164094 |
| mRNA-1189 | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05164094 |
| Placebo | Other | Phase PHASE1 | Methylmalonic Acidemia | TERMINATED | NCT04899310 |
| mRNA-3705 | Other | Phase PHASE1 | Methylmalonic Acidemia | TERMINATED | NCT04899310 |
| Placebo | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05164094 |
| mRNA-1189 | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05164094 |
| Placebo | Other | Phase PHASE1 | Methylmalonic Acidemia | TERMINATED | NCT04899310 |
| mRNA-3705 | Other | Phase PHASE1 | Methylmalonic Acidemia | TERMINATED | NCT04899310 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| Placebo | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05164094 |
| mRNA-1189 | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05164094 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| Pembrolizumab | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| Intismeran autogene | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| mRNA-1345 | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT07117487 |
| Placebo | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Intismeran autogene | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Paclitaxel | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Gemcitabine | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Pemetrexed | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Carboplatin | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Cisplatin | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Pembrolizumab | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| Pembrolizumab | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| Intismeran autogene | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| mRNA-1345 | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT07117487 |
| Placebo | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Intismeran autogene | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Paclitaxel | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Gemcitabine | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Pemetrexed | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Carboplatin | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Cisplatin | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Pembrolizumab | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| Pembrolizumab | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| Intismeran autogene | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| mRNA-1345 | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT07117487 |
| Placebo | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Intismeran autogene | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Paclitaxel | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Gemcitabine | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Pemetrexed | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Carboplatin | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Cisplatin | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Pembrolizumab | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| Placebo | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Intismeran autogene | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Paclitaxel | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Gemcitabine | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Pemetrexed | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Carboplatin | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Cisplatin | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Pembrolizumab | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| Pembrolizumab | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| Intismeran autogene | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| mRNA-1345 | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT07117487 |
| Placebo | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Intismeran autogene | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Paclitaxel | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Gemcitabine | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Pemetrexed | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Carboplatin | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Cisplatin | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Pembrolizumab | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| Pembrolizumab | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| Intismeran autogene | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| mRNA-1345 | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT07117487 |
| Placebo | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Intismeran autogene | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Paclitaxel | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Gemcitabine | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Pemetrexed | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Carboplatin | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Cisplatin | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Pembrolizumab | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| Pembrolizumab | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| Intismeran autogene | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| mRNA-1345 | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT07117487 |
| Placebo | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Intismeran autogene | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Paclitaxel | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Gemcitabine | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Pemetrexed | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Carboplatin | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Cisplatin | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Pembrolizumab | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| Pembrolizumab | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| Intismeran autogene | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| mRNA-1345 | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT07117487 |
| Placebo | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Intismeran autogene | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Paclitaxel | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Gemcitabine | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Pemetrexed | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Carboplatin | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Cisplatin | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Pembrolizumab | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| Pembrolizumab | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| Intismeran autogene | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| mRNA-1345 | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT07117487 |
| Placebo | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Intismeran autogene | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Paclitaxel | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Gemcitabine | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Pemetrexed | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Carboplatin | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Cisplatin | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Pembrolizumab | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| mRNA-1230 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05585632 |
| mRNA-1045 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05585632 |
| mRNA-1273.214 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05585632 |
| mRNA-1345 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05585632 |
| mRNA-1010 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05585632 |
| mRNA-1010.6 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT05868382 |
| mRNA-1010.4 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT05868382 |
| mRNA-1010 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT05868382 |
| mRNA-1010.6 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT05868382 |
| mRNA-1010.4 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT05868382 |
| mRNA-1010 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT05868382 |
| Fluarix Quadrivalent | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05566639 |
| mRNA-1010 | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05566639 |
| Fluarix Quadrivalent | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05566639 |
| mRNA-1010 | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05566639 |
| Fluarix Quadrivalent | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05566639 |
| mRNA-1010 | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05566639 |
| mRNA-1345 | Other | Phase PHASE3 | Respiratory Syncytial Virus | ACTIVE_NOT_RECRUITING | NCT06067230 |
| mRNA-1345 | Other | Phase PHASE3 | Respiratory Syncytial Virus | ACTIVE_NOT_RECRUITING | NCT06067230 |
| Placebo | Other | Phase PHASE1 | Lyme Disease | COMPLETED | NCT05975099 |
| mRNA-1982 | Other | Phase PHASE1 | Lyme Disease | COMPLETED | NCT05975099 |
| mRNA-1975 | Other | Phase PHASE1 | Lyme Disease | COMPLETED | NCT05975099 |
| Placebo | Other | Phase PHASE1 | Lyme Disease | COMPLETED | NCT05975099 |
| mRNA-1982 | Other | Phase PHASE1 | Lyme Disease | COMPLETED | NCT05975099 |
| mRNA-1975 | Other | Phase PHASE1 | Lyme Disease | COMPLETED | NCT05975099 |
| Placebo | Other | Phase PHASE1 | Human Metapneumovirus and Human Parainfluenza Infection | COMPLETED | NCT03392389 |
| mRNA-1653 | Other | Phase PHASE1 | Human Metapneumovirus and Human Parainfluenza Infection | COMPLETED | NCT03392389 |
| Placebo | Other | Phase PHASE1 | Human Metapneumovirus and Human Parainfluenza Infection | COMPLETED | NCT03392389 |
| mRNA-1653 | Other | Phase PHASE1 | Human Metapneumovirus and Human Parainfluenza Infection | COMPLETED | NCT03392389 |
| Placebo | Other | Phase PHASE1 | Human Metapneumovirus and Human Parainfluenza Infection | COMPLETED | NCT03392389 |
| mRNA-1653 | Other | Phase PHASE1 | Human Metapneumovirus and Human Parainfluenza Infection | COMPLETED | NCT03392389 |
| Placebo | Other | Phase PHASE1 | Human Metapneumovirus and Human Parainfluenza Infection | COMPLETED | NCT03392389 |
| mRNA-1653 | Other | Phase PHASE1 | Human Metapneumovirus and Human Parainfluenza Infection | COMPLETED | NCT03392389 |
| mRNA-3704 | Other | Phase PHASE1 | Methylmalonic Acidemia (MMA) | WITHDRAWN | NCT03810690 |
| mRNA-3704 | Other | Phase PHASE1 | Methylmalonic Acidemia (MMA) | WITHDRAWN | NCT03810690 |
| mRNA-3704 | Other | Phase PHASE1 | Methylmalonic Acidemia (MMA) | WITHDRAWN | NCT03810690 |
| Placebo | Other | Phase PHASE1 | Influenza | COMPLETED | NCT03345043 |
| VAL-339851 | Other | Phase PHASE1 | Influenza | COMPLETED | NCT03345043 |
| Placebo | Other | Phase PHASE1 | Influenza | COMPLETED | NCT03345043 |
| VAL-339851 | Other | Phase PHASE1 | Influenza | COMPLETED | NCT03345043 |
| Placebo | Other | Phase PHASE1 | Influenza | COMPLETED | NCT03345043 |
| VAL-339851 | Other | Phase PHASE1 | Influenza | COMPLETED | NCT03345043 |
| Placebo | Other | Phase PHASE1 | Cytomegalovirus Infection | COMPLETED | NCT03382405 |
| mRNA-1443 | Other | Phase PHASE1 | Cytomegalovirus Infection | COMPLETED | NCT03382405 |
| mRNA-1647 | Other | Phase PHASE1 | Cytomegalovirus Infection | COMPLETED | NCT03382405 |
| Placebo | Other | Phase PHASE1 | Cytomegalovirus Infection | COMPLETED | NCT03382405 |
| mRNA-1443 | Other | Phase PHASE1 | Cytomegalovirus Infection | COMPLETED | NCT03382405 |
| mRNA-1647 | Other | Phase PHASE1 | Cytomegalovirus Infection | COMPLETED | NCT03382405 |
| Placebo | Other | Phase PHASE1 | Cytomegalovirus Infection | COMPLETED | NCT03382405 |
| mRNA-1443 | Other | Phase PHASE1 | Cytomegalovirus Infection | COMPLETED | NCT03382405 |
| mRNA-1647 | Other | Phase PHASE1 | Cytomegalovirus Infection | COMPLETED | NCT03382405 |
| Placebo | Other | Phase PHASE1 | Prevention of Chikungunya Virus Infection | COMPLETED | NCT03829384 |
| mRNA-1944 | Other | Phase PHASE1 | Prevention of Chikungunya Virus Infection | COMPLETED | NCT03829384 |
| Placebo | Other | Phase PHASE1 | Prevention of Chikungunya Virus Infection | COMPLETED | NCT03829384 |
| mRNA-1944 | Other | Phase PHASE1 | Prevention of Chikungunya Virus Infection | COMPLETED | NCT03829384 |
| Placebo | Other | Phase PHASE1 | Prevention of Chikungunya Virus Infection | COMPLETED | NCT03829384 |
| mRNA-1944 | Other | Phase PHASE1 | Prevention of Chikungunya Virus Infection | COMPLETED | NCT03829384 |
| Placebo | Other | Phase PHASE1 | Influenza | COMPLETED | NCT03076385 |
| VAL-506440 | Other | Phase PHASE1 | Influenza | COMPLETED | NCT03076385 |
| Placebo | Other | Phase PHASE1 | Influenza | COMPLETED | NCT03076385 |
| VAL-506440 | Other | Phase PHASE1 | Influenza | COMPLETED | NCT03076385 |
| Placebo | Other | Phase PHASE1 | Influenza | COMPLETED | NCT03076385 |
| VAL-506440 | Other | Phase PHASE1 | Influenza | COMPLETED | NCT03076385 |
| Placebo | Other | Phase PHASE1 | Influenza | COMPLETED | NCT03076385 |
| VAL-506440 | Other | Phase PHASE1 | Influenza | COMPLETED | NCT03076385 |
| mRNA-6231 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04916431 |
| mRNA-6231 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04916431 |
| mRNA-6231 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04916431 |
| mRNA-1273.351 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04405076 |
| Placebo | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04405076 |
| Biological: mRNA-1273 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04405076 |
| mRNA-1273.351 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04405076 |
| Placebo | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04405076 |
| Biological: mRNA-1273 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04405076 |
| Placebo | Other | Phase PHASE1 | Human Metapneumovirus and Human Parainfluenza Infection | COMPLETED | NCT04144348 |
| mRNA-1653 | Other | Phase PHASE1 | Human Metapneumovirus and Human Parainfluenza Infection | COMPLETED | NCT04144348 |
| Placebo | Other | Phase PHASE1 | Human Metapneumovirus and Human Parainfluenza Infection | COMPLETED | NCT04144348 |
| mRNA-1653 | Other | Phase PHASE1 | Human Metapneumovirus and Human Parainfluenza Infection | COMPLETED | NCT04144348 |
| Placebo | Other | Phase PHASE1 | Human Metapneumovirus and Human Parainfluenza Infection | COMPLETED | NCT04144348 |
| mRNA-1653 | Other | Phase PHASE1 | Human Metapneumovirus and Human Parainfluenza Infection | COMPLETED | NCT04144348 |
| eOD-GT8 60mer mRNA Vaccine (100µg) | Other | Phase PHASE1 | HIV-1-infection | UNKNOWN | NCT05414786 |
| eOD-GT8 60mer mRNA Vaccine (100µg) | Other | Phase PHASE1 | HIV-1-infection | UNKNOWN | NCT05414786 |
| eOD-GT8 60mer mRNA Vaccine (100µg) | Other | Phase PHASE1 | HIV-1-infection | UNKNOWN | NCT05414786 |
| Wireless wearable digital devices | Device | Preclinical | Healthy Participants | COMPLETED | NCT05440318 |
| Wireless wearable digital devices | Device | Preclinical | Healthy Participants | COMPLETED | NCT05440318 |
| Wireless wearable digital devices | Device | Preclinical | Healthy Participants | COMPLETED | NCT05440318 |
| mRNA-1273 | Other | Preclinical | Covid19 | COMPLETED | NCT05054218 |
| mRNA-1273 | Other | Preclinical | Covid19 | COMPLETED | NCT05054218 |
| mRNA-1273 | Other | Preclinical | Covid19 | COMPLETED | NCT05054218 |
| mRNA-1273 | Other | Preclinical | Covid19 | COMPLETED | NCT05054218 |
| COVID-19 Vaccine | Other | Preclinical | Coronavirus Disease (COVID-19) | COMPLETED | NCT04941144 |
| COVID-19 Vaccine | Other | Preclinical | Coronavirus Disease (COVID-19) | COMPLETED | NCT04941144 |
| Placebo | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT04813796 |
| mRNA-1273 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT04813796 |
| mRNA-1283 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT04813796 |
| Placebo | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT04813796 |
| mRNA-1273 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT04813796 |
| mRNA-1283 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT04813796 |
| Placebo | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT04813796 |
| mRNA-1273 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT04813796 |
| mRNA-1283 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT04813796 |
| mRNA-2736 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | WITHDRAWN | NCT05918250 |
| mRNA-2736 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | WITHDRAWN | NCT05918250 |
| mRNA-2736 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | WITHDRAWN | NCT05918250 |
| mRNA-2736 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | WITHDRAWN | NCT05918250 |
| Placebo | Other | Phase PHASE1 | Cytomegalovirus Infection | COMPLETED | NCT05105048 |
| mRNA-1647 | Other | Phase PHASE1 | Cytomegalovirus Infection | COMPLETED | NCT05105048 |
| Placebo | Other | Phase PHASE1 | Cytomegalovirus Infection | COMPLETED | NCT05105048 |
| mRNA-1647 | Other | Phase PHASE1 | Cytomegalovirus Infection | COMPLETED | NCT05105048 |
| Placebo | Other | Phase PHASE1 | Cytomegalovirus Infection | COMPLETED | NCT05105048 |
| mRNA-1647 | Other | Phase PHASE1 | Cytomegalovirus Infection | COMPLETED | NCT05105048 |
| Active Comparator | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT04956575 |
| Placebo | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT04956575 |
| mRNA-1010 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT04956575 |
| Active Comparator | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT04956575 |
| Placebo | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT04956575 |
| mRNA-1010 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT04956575 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04232280 |
| Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®) | Other | Phase PHASE3 | Immunocompromised Patients | COMPLETED | NCT04805125 |
| Moderna COVID-19 Vaccine, mRNA-1273 (100 μg) | Other | Phase PHASE3 | Immunocompromised Patients | COMPLETED | NCT04805125 |
| Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®) | Other | Phase PHASE3 | Immunocompromised Patients | COMPLETED | NCT04805125 |
| Moderna COVID-19 Vaccine, mRNA-1273 (100 μg) | Other | Phase PHASE3 | Immunocompromised Patients | COMPLETED | NCT04805125 |
| Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®) | Other | Phase PHASE3 | Immunocompromised Patients | COMPLETED | NCT04805125 |
| Moderna COVID-19 Vaccine, mRNA-1273 (100 μg) | Other | Phase PHASE3 | Immunocompromised Patients | COMPLETED | NCT04805125 |
| Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®) | Other | Phase PHASE3 | Immunocompromised Patients | COMPLETED | NCT04805125 |
| Moderna COVID-19 Vaccine, mRNA-1273 (100 μg) | Other | Phase PHASE3 | Immunocompromised Patients | COMPLETED | NCT04805125 |
| Active Comparator | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05333289 |
| mRNA-1010 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05333289 |
| mRNA-1020 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05333289 |
| mRNA-1030 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05333289 |
| Active Comparator | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05333289 |
| mRNA-1010 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05333289 |
| mRNA-1020 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05333289 |
| mRNA-1030 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05333289 |
| Active Comparator | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05333289 |
| mRNA-1010 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05333289 |
| mRNA-1020 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05333289 |
| mRNA-1030 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05333289 |
| MRNA-1273.222 Vaccine | Other | Phase PHASE2 | COVID-19 Pandemic | COMPLETED | NCT05383560 |
| Placebo | Other | Phase PHASE2 | COVID-19 Pandemic | COMPLETED | NCT05383560 |
| MRNA-1273 Vaccine | Other | Phase PHASE2 | COVID-19 Pandemic | COMPLETED | NCT05383560 |
| mRNA-1273.214 Vaccine | Other | Phase PHASE2 | COVID-19 Pandemic | COMPLETED | NCT05383560 |
| MRNA-1273.222 Vaccine | Other | Phase PHASE2 | COVID-19 Pandemic | COMPLETED | NCT05383560 |
| Placebo | Other | Phase PHASE2 | COVID-19 Pandemic | COMPLETED | NCT05383560 |
| MRNA-1273 Vaccine | Other | Phase PHASE2 | COVID-19 Pandemic | COMPLETED | NCT05383560 |
| mRNA-1273.214 Vaccine | Other | Phase PHASE2 | COVID-19 Pandemic | COMPLETED | NCT05383560 |
| MRNA-1273.222 Vaccine | Other | Phase PHASE2 | COVID-19 Pandemic | COMPLETED | NCT05383560 |
| Placebo | Other | Phase PHASE2 | COVID-19 Pandemic | COMPLETED | NCT05383560 |
| MRNA-1273 Vaccine | Other | Phase PHASE2 | COVID-19 Pandemic | COMPLETED | NCT05383560 |
| mRNA-1273.214 Vaccine | Other | Phase PHASE2 | COVID-19 Pandemic | COMPLETED | NCT05383560 |
| Placebo | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05375838 |
| mRNA-1273 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05375838 |
| mRNA-1010 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05375838 |
| mRNA-1073 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05375838 |
| Placebo | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05375838 |
| mRNA-1273 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05375838 |
| mRNA-1010 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05375838 |
| mRNA-1073 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05375838 |
| Placebo | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05375838 |
| mRNA-1273 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05375838 |
| mRNA-1010 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05375838 |
| mRNA-1073 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05375838 |
| mRNA-1230 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05585632 |
| mRNA-1045 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05585632 |
| mRNA-1273.214 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05585632 |
| mRNA-1345 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05585632 |
| mRNA-1010 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05585632 |
| mRNA-1230 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05585632 |
| mRNA-1045 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05585632 |
| mRNA-1273.214 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05585632 |
| mRNA-1345 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05585632 |
| mRNA-1010 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05585632 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | WITHDRAWN | NCT06133010 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | WITHDRAWN | NCT06133010 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | WITHDRAWN | NCT06133010 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | WITHDRAWN | NCT06133010 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | WITHDRAWN | NCT06133010 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | WITHDRAWN | NCT06133010 |
| mRNA-1273.351 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04785144 |
| mRNA-1273 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04785144 |
| mRNA-1273.351 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04785144 |
| mRNA-1273 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04785144 |
| mRNA-1273.351 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04785144 |
| mRNA-1273 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04785144 |
| mRNA-1273 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04283461 |
| mRNA-1273 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04283461 |
| Placebo | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT04470427 |
| mRNA-1273 | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT04470427 |
| Placebo | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT04470427 |
| mRNA-1273 | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT04470427 |
| eOD-GT8 60mer mRNA Vaccine | Other | Phase PHASE1 | Hiv | ACTIVE_NOT_RECRUITING | NCT05001373 |
| Core-g28v2 60mer mRNA Vaccine | Other | Phase PHASE1 | Hiv | ACTIVE_NOT_RECRUITING | NCT05001373 |
| eOD-GT8 60mer mRNA Vaccine | Other | Phase PHASE1 | Hiv | ACTIVE_NOT_RECRUITING | NCT05001373 |
| Core-g28v2 60mer mRNA Vaccine | Other | Phase PHASE1 | Hiv | ACTIVE_NOT_RECRUITING | NCT05001373 |
| eOD-GT8 60mer mRNA Vaccine | Other | Phase PHASE1 | Hiv | ACTIVE_NOT_RECRUITING | NCT05001373 |
| Core-g28v2 60mer mRNA Vaccine | Other | Phase PHASE1 | Hiv | ACTIVE_NOT_RECRUITING | NCT05001373 |
| Placebo | Other | Phase PHASE1 | Chikungunya Virus | COMPLETED | NCT03325075 |
| VAL-181388 | Other | Phase PHASE1 | Chikungunya Virus | COMPLETED | NCT03325075 |
| Placebo | Other | Phase PHASE1 | Chikungunya Virus | COMPLETED | NCT03325075 |
| VAL-181388 | Other | Phase PHASE1 | Chikungunya Virus | COMPLETED | NCT03325075 |
| Placebo | Other | Phase PHASE1 | Chikungunya Virus | COMPLETED | NCT03325075 |
| VAL-181388 | Other | Phase PHASE1 | Chikungunya Virus | COMPLETED | NCT03325075 |
| Patient Reported Outcomes | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05831787 |
| Patient Reported Outcomes | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05831787 |
| Patient Reported Outcomes | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05831787 |
| mRNA-1273 | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT04860297 |
| mRNA-1273 | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT04860297 |
| mRNA-1273 | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT04860297 |
| mRNA-1273 | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT04860297 |
| CMV PCR on saliva | Other | Preclinical | Cytomegalovirus Infections | RECRUITING | NCT06522880 |
| CMV PCR on saliva | Other | Preclinical | Cytomegalovirus Infections | RECRUITING | NCT06522880 |
| CMV PCR on saliva | Other | Preclinical | Cytomegalovirus Infections | RECRUITING | NCT06522880 |
| Pfizer 2023 Updated COVID-19 vaccine (XBB.1.5) | Other | Preclinical | COVID-19 | COMPLETED | NCT05765578 |
| Moderna 2023 Updated COVID-19 vaccine (XBB.1.5) | Other | Preclinical | COVID-19 | COMPLETED | NCT05765578 |
| Pfizer COVID-19 Vaccine | Other | Preclinical | COVID-19 | COMPLETED | NCT05765578 |
| Moderna mRNA1273.222 Booster | Other | Preclinical | COVID-19 | COMPLETED | NCT05765578 |
| Moderna COVID-19 Vaccine | Other | Preclinical | COVID-19 | COMPLETED | NCT05765578 |
| Pfizer 2023 Updated COVID-19 vaccine (XBB.1.5) | Other | Preclinical | COVID-19 | COMPLETED | NCT05765578 |
| Moderna 2023 Updated COVID-19 vaccine (XBB.1.5) | Other | Preclinical | COVID-19 | COMPLETED | NCT05765578 |
| Pfizer COVID-19 Vaccine | Other | Preclinical | COVID-19 | COMPLETED | NCT05765578 |
| Moderna mRNA1273.222 Booster | Other | Preclinical | COVID-19 | COMPLETED | NCT05765578 |
| Moderna COVID-19 Vaccine | Other | Preclinical | COVID-19 | COMPLETED | NCT05765578 |
| Pfizer 2023 Updated COVID-19 vaccine (XBB.1.5) | Other | Preclinical | COVID-19 | COMPLETED | NCT05765578 |
| Moderna 2023 Updated COVID-19 vaccine (XBB.1.5) | Other | Preclinical | COVID-19 | COMPLETED | NCT05765578 |
| Pfizer COVID-19 Vaccine | Other | Preclinical | COVID-19 | COMPLETED | NCT05765578 |
| Moderna mRNA1273.222 Booster | Other | Preclinical | COVID-19 | COMPLETED | NCT05765578 |
| Moderna COVID-19 Vaccine | Other | Preclinical | COVID-19 | COMPLETED | NCT05765578 |
| Durvalumab | Other | Phase PHASE1 | Relapsed/Refractory Solid Tumor Malignancies or Lymphoma | TERMINATED | NCT03323398 |
| mRNA-2416 | Other | Phase PHASE1 | Relapsed/Refractory Solid Tumor Malignancies or Lymphoma | TERMINATED | NCT03323398 |
| Durvalumab | Other | Phase PHASE1 | Relapsed/Refractory Solid Tumor Malignancies or Lymphoma | TERMINATED | NCT03323398 |
| mRNA-2416 | Other | Phase PHASE1 | Relapsed/Refractory Solid Tumor Malignancies or Lymphoma | TERMINATED | NCT03323398 |
| Durvalumab | Other | Phase PHASE1 | Relapsed/Refractory Solid Tumor Malignancies or Lymphoma | TERMINATED | NCT03323398 |
| mRNA-2416 | Other | Phase PHASE1 | Relapsed/Refractory Solid Tumor Malignancies or Lymphoma | TERMINATED | NCT03323398 |
| Placebo | Other | Phase PHASE1 | Respiratory Syncytial Virus | COMPLETED | NCT04528719 |
| mRNA-1345 | Other | Phase PHASE1 | Respiratory Syncytial Virus | COMPLETED | NCT04528719 |
| Placebo | Other | Phase PHASE1 | Respiratory Syncytial Virus | COMPLETED | NCT04528719 |
| mRNA-1345 | Other | Phase PHASE1 | Respiratory Syncytial Virus | COMPLETED | NCT04528719 |
| Placebo | Other | Phase PHASE1 | Respiratory Syncytial Virus | COMPLETED | NCT04528719 |
| mRNA-1345 | Other | Phase PHASE1 | Respiratory Syncytial Virus | COMPLETED | NCT04528719 |
| mRNA-1273.214 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05249829 |
| mRNA-1273 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05249829 |
| mRNA-1273.529 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05249829 |
| mRNA-1273.214 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05249829 |
| mRNA-1273 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05249829 |
| mRNA-1273.529 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05249829 |
| mRNA-1273.214 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05249829 |
| mRNA-1273 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05249829 |
| mRNA-1273.529 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05249829 |
| Placebo | Other | Phase PHASE1 | Zika Virus | COMPLETED | NCT04064905 |
| mRNA-1893 | Other | Phase PHASE1 | Zika Virus | COMPLETED | NCT04064905 |
| Placebo | Other | Phase PHASE1 | Zika Virus | COMPLETED | NCT04064905 |
| mRNA-1893 | Other | Phase PHASE1 | Zika Virus | COMPLETED | NCT04064905 |
| Placebo | Other | Phase PHASE1 | Zika Virus | COMPLETED | NCT04064905 |
| mRNA-1893 | Other | Phase PHASE1 | Zika Virus | COMPLETED | NCT04064905 |
| Placebo | Other | Phase PHASE1 | Zika Virus | COMPLETED | NCT03014089 |
| mRNA-1325 | Other | Phase PHASE1 | Zika Virus | COMPLETED | NCT03014089 |
| Placebo | Other | Phase PHASE1 | Zika Virus | COMPLETED | NCT03014089 |
| mRNA-1325 | Other | Phase PHASE1 | Zika Virus | COMPLETED | NCT03014089 |
| Fluarix Tetra | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05415462 |
| mRNA-1010 | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05415462 |
| Fluarix Tetra | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05415462 |
| mRNA-1010 | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05415462 |
| Fluarix Tetra | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05415462 |
| mRNA-1010 | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05415462 |
| Fluarix Tetra | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05415462 |
| mRNA-1010 | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05415462 |
| mRNA-3210 | Other | Phase PHASE1 | Phenylketonuria | WITHDRAWN | NCT06147856 |
| mRNA-3210 | Other | Phase PHASE1 | Phenylketonuria | WITHDRAWN | NCT06147856 |
| SPIKEVAX | Other | Preclinical | SARS-CoV-2 | COMPLETED | NCT06130345 |
| SPIKEVAX | Other | Preclinical | SARS-CoV-2 | COMPLETED | NCT06130345 |
| SPIKEVAX | Other | Preclinical | SARS-CoV-2 | COMPLETED | NCT06130345 |
| mRNA-1010.6 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT05868382 |
| mRNA-1010.4 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT05868382 |
| mRNA-1010 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT05868382 |
| No intervention | Other | Preclinical | SARS-CoV-2 Infection | COMPLETED | NCT05794412 |
| No intervention | Other | Preclinical | SARS-CoV-2 Infection | COMPLETED | NCT05794412 |
| No intervention | Other | Preclinical | SARS-CoV-2 Infection | COMPLETED | NCT05794412 |
| No intervention | Other | Preclinical | SARS-CoV-2 Infection | COMPLETED | NCT05794412 |
| Placebo | Other | Preclinical | Respiratory Syncytial Virus | COMPLETED | NCT05572658 |
| mRNA-1345 | Other | Preclinical | Respiratory Syncytial Virus | COMPLETED | NCT05572658 |
| Placebo | Other | Preclinical | Respiratory Syncytial Virus | COMPLETED | NCT05572658 |
| mRNA-1345 | Other | Preclinical | Respiratory Syncytial Virus | COMPLETED | NCT05572658 |
| Placebo | Other | Preclinical | Respiratory Syncytial Virus | COMPLETED | NCT05572658 |
| mRNA-1345 | Other | Preclinical | Respiratory Syncytial Virus | COMPLETED | NCT05572658 |
| Placebo | Other | Preclinical | Respiratory Syncytial Virus | COMPLETED | NCT05572658 |
| mRNA-1345 | Other | Preclinical | Respiratory Syncytial Virus | COMPLETED | NCT05572658 |
| Pembrolizumab | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT03948763 |
| V941 | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT03948763 |
| Pembrolizumab | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT03948763 |
| V941 | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT03948763 |
| Pembrolizumab | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT03948763 |
| V941 | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT03948763 |
| Pembrolizumab | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT03948763 |
| V941 | Other | Phase PHASE1 | Neoplasms | TERMINATED | NCT03948763 |
| Intralesional mRNA 2752 | Other | Phase EARLY_PHASE1 | Carcinoma, Intraductal, Noninfiltrating | ACTIVE_NOT_RECRUITING | NCT02872025 |
| Pembrolizumab | Other | Phase EARLY_PHASE1 | Carcinoma, Intraductal, Noninfiltrating | ACTIVE_NOT_RECRUITING | NCT02872025 |
| Intralesional mRNA 2752 | Other | Phase EARLY_PHASE1 | Carcinoma, Intraductal, Noninfiltrating | ACTIVE_NOT_RECRUITING | NCT02872025 |
| Pembrolizumab | Other | Phase EARLY_PHASE1 | Carcinoma, Intraductal, Noninfiltrating | ACTIVE_NOT_RECRUITING | NCT02872025 |
| Intralesional mRNA 2752 | Other | Phase EARLY_PHASE1 | Carcinoma, Intraductal, Noninfiltrating | ACTIVE_NOT_RECRUITING | NCT02872025 |
| Pembrolizumab | Other | Phase EARLY_PHASE1 | Carcinoma, Intraductal, Noninfiltrating | ACTIVE_NOT_RECRUITING | NCT02872025 |
| mRNA-1010.3 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05827068 |
| mRNA-1010.2 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05827068 |
| mRNA-1010 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05827068 |
| mRNA-1012.1 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05827068 |
| mRNA-1011.2 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05827068 |
| mRNA-1011.1 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05827068 |
| mRNA-1010.3 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05827068 |
| mRNA-1010.2 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05827068 |
| mRNA-1010 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05827068 |
| mRNA-1012.1 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05827068 |
| mRNA-1011.2 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05827068 |
| mRNA-1011.1 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05827068 |
| mRNA-1010.3 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05827068 |
| mRNA-1010.2 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05827068 |
| mRNA-1010 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05827068 |
| mRNA-1012.1 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05827068 |
| mRNA-1011.2 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05827068 |
| mRNA-1011.1 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05827068 |
| mRNA-1010.3 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05827068 |
| mRNA-1010.2 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05827068 |
| mRNA-1010 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05827068 |
| mRNA-1012.1 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05827068 |
| mRNA-1011.2 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05827068 |
| mRNA-1011.1 | Other | Phase PHASE1 | Seasonal Influenza | COMPLETED | NCT05827068 |
| mRNA-1273.231 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| mRNA-1273.815 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| mRNA-1273.222 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| mRNA-1273.214 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| mRNA-1273.529 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| mRNA-1273.213 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| mRNA-1273.617.2 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| mRNA-1273 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| mRNA-1273.211 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| mRNA-1273.231 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| mRNA-1273.815 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| mRNA-1273.222 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| mRNA-1273.214 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| mRNA-1273.529 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| mRNA-1273.213 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| mRNA-1273.617.2 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| mRNA-1273 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| mRNA-1273.211 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| mRNA-1273.231 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| mRNA-1273.815 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| mRNA-1273.222 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| mRNA-1273.214 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| mRNA-1273.529 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| mRNA-1273.213 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| mRNA-1273.617.2 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| mRNA-1273 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| mRNA-1273.211 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04927065 |
| Placebo | Other | Phase PHASE1 | Chronic Heart Failure | COMPLETED | NCT05659264 |
| mRNA-0184 | Other | Phase PHASE1 | Chronic Heart Failure | COMPLETED | NCT05659264 |
| Placebo | Other | Phase PHASE1 | Chronic Heart Failure | COMPLETED | NCT05659264 |
| mRNA-0184 | Other | Phase PHASE1 | Chronic Heart Failure | COMPLETED | NCT05659264 |
| Placebo | Other | Phase PHASE1 | Chronic Heart Failure | COMPLETED | NCT05659264 |
| mRNA-0184 | Other | Phase PHASE1 | Chronic Heart Failure | COMPLETED | NCT05659264 |
| SPIKEVAX X | Other | Preclinical | SARS-CoV-2 | RECRUITING | NCT06333704 |
| SPIKEVAX Bivalent | Other | Preclinical | SARS-CoV-2 | RECRUITING | NCT06333704 |
| mRNA-1273 (Moderna COVID-19 vaccine) | Other | Phase PHASE1 | Lung Transplant Recipient | TERMINATED | NCT05280158 |
| mRNA-1273 (Moderna COVID-19 vaccine) | Other | Phase PHASE1 | Lung Transplant Recipient | TERMINATED | NCT05280158 |
| mRNA-1273.815 | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT05815498 |
| mRNA-1283.815 | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT05815498 |
| mRNA-1273.222 | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT05815498 |
| mRNA-1283.222 | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT05815498 |
| mRNA-1273.815 | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT05815498 |
| mRNA-1283.815 | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT05815498 |
| mRNA-1273.222 | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT05815498 |
| mRNA-1283.222 | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT05815498 |
| BEXSERO | Other | Phase PHASE1 | Genital Herpes | COMPLETED | NCT06033261 |
| mRNA-1608 | Other | Phase PHASE1 | Genital Herpes | COMPLETED | NCT06033261 |
| BEXSERO | Other | Phase PHASE1 | Genital Herpes | COMPLETED | NCT06033261 |
| mRNA-1608 | Other | Phase PHASE1 | Genital Herpes | COMPLETED | NCT06033261 |
| Placebo | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05164094 |
| mRNA-1189 | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05164094 |
| Placebo | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05164094 |
| mRNA-1189 | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05164094 |
| Placebo | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05164094 |
| mRNA-1189 | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05164094 |
| Licensed Spikevax Vaccine | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT06354998 |
| Investigational mRNA-1273.815 | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT06354998 |
| Licensed Spikevax Vaccine | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT06354998 |
| Investigational mRNA-1273.815 | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT06354998 |
| Licensed Spikevax Vaccine | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT06354998 |
| Investigational mRNA-1273.815 | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT06354998 |
| mRNA-1273.214 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04796896 |
| Placebo | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04796896 |
| mRNA-1273 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04796896 |
| mRNA-1273.214 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04796896 |
| Placebo | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04796896 |
| mRNA-1273 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04796896 |
| COVID-19 Vaccine | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT06097273 |
| Influenza Vaccine | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT06097273 |
| Placebo | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT06097273 |
| mRNA-1083 | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT06097273 |
| COVID-19 Vaccine | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT06097273 |
| Influenza Vaccine | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT06097273 |
| Placebo | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT06097273 |
| mRNA-1083 | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT06097273 |
| COVID-19 Vaccine | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT06097273 |
| Influenza Vaccine | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT06097273 |
| Placebo | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT06097273 |
| mRNA-1083 | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT06097273 |
| Placebo | Other | Phase PHASE2 | Respiratory Syncytial Virus | COMPLETED | NCT06097299 |
| mRNA-1345 | Other | Phase PHASE2 | Respiratory Syncytial Virus | COMPLETED | NCT06097299 |
| Placebo | Other | Phase PHASE2 | Respiratory Syncytial Virus | COMPLETED | NCT06097299 |
| mRNA-1345 | Other | Phase PHASE2 | Respiratory Syncytial Virus | COMPLETED | NCT06097299 |
| Placebo | Other | Phase PHASE2 | Respiratory Syncytial Virus | COMPLETED | NCT06097299 |
| mRNA-1345 | Other | Phase PHASE2 | Respiratory Syncytial Virus | COMPLETED | NCT06097299 |
| Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05827978 |
| mRNA-1010 | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05827978 |
| Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05827978 |
| mRNA-1010 | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05827978 |
| Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05827978 |
| mRNA-1010 | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05827978 |
| Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05827978 |
| mRNA-1010 | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT05827978 |
| Placebo | Other | Phase PHASE1 | Smallpox | COMPLETED | NCT05995275 |
| mRNA-1769 | Other | Phase PHASE1 | Smallpox | COMPLETED | NCT05995275 |
| Placebo | Other | Phase PHASE1 | Smallpox | COMPLETED | NCT05995275 |
| mRNA-1769 | Other | Phase PHASE1 | Smallpox | COMPLETED | NCT05995275 |
| Placebo | Other | Phase PHASE1 | Smallpox | COMPLETED | NCT05995275 |
| mRNA-1769 | Other | Phase PHASE1 | Smallpox | COMPLETED | NCT05995275 |
| mRNA-1018 for H5 Only-CG | Other | Phase PHASE1 | Influenza | COMPLETED | NCT05972174 |
| mRNA-1018 for H7 Only | Other | Phase PHASE1 | Influenza | COMPLETED | NCT05972174 |
| mRNA-1018 for H5 Only | Other | Phase PHASE1 | Influenza | COMPLETED | NCT05972174 |
| mRNA-1018 for H7N9 | Other | Phase PHASE1 | Influenza | COMPLETED | NCT05972174 |
| mRNA-1018 for H5N8 | Other | Phase PHASE1 | Influenza | COMPLETED | NCT05972174 |
| mRNA-1018 for H5 Only-CG | Other | Phase PHASE1 | Influenza | COMPLETED | NCT05972174 |
| mRNA-1018 for H7 Only | Other | Phase PHASE1 | Influenza | COMPLETED | NCT05972174 |
| mRNA-1018 for H5 Only | Other | Phase PHASE1 | Influenza | COMPLETED | NCT05972174 |
| mRNA-1018 for H7N9 | Other | Phase PHASE1 | Influenza | COMPLETED | NCT05972174 |
| mRNA-1018 for H5N8 | Other | Phase PHASE1 | Influenza | COMPLETED | NCT05972174 |
| mRNA-1018 for H5 Only-CG | Other | Phase PHASE1 | Influenza | COMPLETED | NCT05972174 |
| mRNA-1018 for H7 Only | Other | Phase PHASE1 | Influenza | COMPLETED | NCT05972174 |
| mRNA-1018 for H5 Only | Other | Phase PHASE1 | Influenza | COMPLETED | NCT05972174 |
| mRNA-1018 for H7N9 | Other | Phase PHASE1 | Influenza | COMPLETED | NCT05972174 |
| mRNA-1018 for H5N8 | Other | Phase PHASE1 | Influenza | COMPLETED | NCT05972174 |
| mRNA-1283.529 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05137236 |
| mRNA-1273 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05137236 |
| mRNA-1283.211 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05137236 |
| mRNA-1283 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05137236 |
| mRNA-1283.529 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05137236 |
| mRNA-1273 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05137236 |
| mRNA-1283.211 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05137236 |
| mRNA-1283 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05137236 |
| mRNA-1283.529 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05137236 |
| mRNA-1273 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05137236 |
| mRNA-1283.211 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05137236 |
| mRNA-1283 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT05137236 |
| Fluzone HD | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT06060457 |
| mRNA-1345 | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT06060457 |
| Placebo | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT06060457 |
| Fluzone HD | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT06060457 |
| mRNA-1345 | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT06060457 |
| Placebo | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT06060457 |
| mRNA-0184 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06243770 |
| mRNA-0184 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06243770 |
| mRNA-0184 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06243770 |
| mRNA-0184 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06243770 |
| mRNA-1273 | Other | Preclinical | Myocarditis, Pericarditis | COMPLETED | NCT06113692 |
| mRNA-1273 | Other | Preclinical | Myocarditis, Pericarditis | COMPLETED | NCT06113692 |
| mRNA-1273 | Other | Preclinical | Myocarditis, Pericarditis | COMPLETED | NCT06113692 |
| mRNA-1273 | Other | Preclinical | Myocarditis, Pericarditis | COMPLETED | NCT06113692 |
| Patient letter and clinician communication | Other | Approved | COVID-19 Immunisation | COMPLETED | NCT06646406 |
| Patient letter and clinician communication | Other | Approved | COVID-19 Immunisation | COMPLETED | NCT06646406 |
| Patient letter and clinician communication | Other | Approved | COVID-19 Immunisation | COMPLETED | NCT06646406 |
| Shingrix | Other | Phase PHASE1 | Herpes Zoster | ACTIVE_NOT_RECRUITING | NCT05701800 |
| Placebo | Other | Phase PHASE1 | Herpes Zoster | ACTIVE_NOT_RECRUITING | NCT05701800 |
| mRNA-1468 | Other | Phase PHASE1 | Herpes Zoster | ACTIVE_NOT_RECRUITING | NCT05701800 |
| Shingrix | Other | Phase PHASE1 | Herpes Zoster | ACTIVE_NOT_RECRUITING | NCT05701800 |
| Placebo | Other | Phase PHASE1 | Herpes Zoster | ACTIVE_NOT_RECRUITING | NCT05701800 |
| mRNA-1468 | Other | Phase PHASE1 | Herpes Zoster | ACTIVE_NOT_RECRUITING | NCT05701800 |
| Shingrix | Other | Phase PHASE1 | Herpes Zoster | ACTIVE_NOT_RECRUITING | NCT05701800 |
| Placebo | Other | Phase PHASE1 | Herpes Zoster | ACTIVE_NOT_RECRUITING | NCT05701800 |
| mRNA-1468 | Other | Phase PHASE1 | Herpes Zoster | ACTIVE_NOT_RECRUITING | NCT05701800 |
| Durvalumab | Other | Phase PHASE1 | Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma | COMPLETED | NCT03739931 |
| mRNA-2752 | Other | Phase PHASE1 | Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma | COMPLETED | NCT03739931 |
| Durvalumab | Other | Phase PHASE1 | Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma | COMPLETED | NCT03739931 |
| mRNA-2752 | Other | Phase PHASE1 | Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma | COMPLETED | NCT03739931 |
| Durvalumab | Other | Phase PHASE1 | Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma | COMPLETED | NCT03739931 |
| mRNA-2752 | Other | Phase PHASE1 | Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma | COMPLETED | NCT03739931 |
| mRNA-1345 | Other | Phase PHASE2 | Respiratory Syncytial Virus | COMPLETED | NCT05127434 |
| Placebo | Other | Phase PHASE2 | Respiratory Syncytial Virus | COMPLETED | NCT05127434 |
| mRNA-1345 | Other | Phase PHASE2 | Respiratory Syncytial Virus | COMPLETED | NCT05127434 |
| Placebo | Other | Phase PHASE2 | Respiratory Syncytial Virus | COMPLETED | NCT05127434 |
| mRNA-1345 | Other | Phase PHASE2 | Respiratory Syncytial Virus | COMPLETED | NCT05127434 |
| Placebo | Other | Phase PHASE2 | Respiratory Syncytial Virus | COMPLETED | NCT05127434 |
| Placebo | Other | Phase PHASE1 | Lyme Disease | COMPLETED | NCT05975099 |
| mRNA-1982 | Other | Phase PHASE1 | Lyme Disease | COMPLETED | NCT05975099 |
| mRNA-1975 | Other | Phase PHASE1 | Lyme Disease | COMPLETED | NCT05975099 |
| Placebo | Other | Phase PHASE2 | Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06307431 |
| Pembrolizumab | Other | Phase PHASE2 | Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06307431 |
| Intismeran autogene | Other | Phase PHASE2 | Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06307431 |
| Placebo | Other | Phase PHASE2 | Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06307431 |
| Pembrolizumab | Other | Phase PHASE2 | Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06307431 |
| Intismeran autogene | Other | Phase PHASE2 | Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06307431 |
| Placebo | Other | Phase PHASE2 | Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06307431 |
| Pembrolizumab | Other | Phase PHASE2 | Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06307431 |
| Intismeran autogene | Other | Phase PHASE2 | Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06307431 |
| Alpharix® Tetra | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT06602024 |
| Fluarix Tetra | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT06602024 |
| Influsplit® Tetra | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT06602024 |
| Fluarix® | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT06602024 |
| mRNA-1010 | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT06602024 |
| Alpharix® Tetra | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT06602024 |
| Fluarix Tetra | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT06602024 |
| Influsplit® Tetra | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT06602024 |
| Fluarix® | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT06602024 |
| mRNA-1010 | Other | Phase PHASE3 | Seasonal Influenza | COMPLETED | NCT06602024 |
| mRNA-1273.222 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04649151 |
| Placebo | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04649151 |
| mRNA-1273 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04649151 |
| mRNA-1273.222 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04649151 |
| Placebo | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04649151 |
| mRNA-1273 | Other | Phase PHASE2 | SARS-CoV-2 | COMPLETED | NCT04649151 |
| Placebo | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05933577 |
| Pembrolizumab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05933577 |
| Intismeran autogene | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05933577 |
| Placebo | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05933577 |
| Pembrolizumab | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05933577 |
| Intismeran autogene | Other | Phase PHASE3 | Melanoma | ACTIVE_NOT_RECRUITING | NCT05933577 |
| Placebo | Other | Phase PHASE2 | Zika Virus | COMPLETED | NCT04917861 |
| mRNA-1893 | Other | Phase PHASE2 | Zika Virus | COMPLETED | NCT04917861 |
| Placebo | Other | Phase PHASE2 | Zika Virus | COMPLETED | NCT04917861 |
| mRNA-1893 | Other | Phase PHASE2 | Zika Virus | COMPLETED | NCT04917861 |
| Placebo | Other | Phase PHASE2 | Zika Virus | COMPLETED | NCT04917861 |
| mRNA-1893 | Other | Phase PHASE2 | Zika Virus | COMPLETED | NCT04917861 |
| mRNA-1195 | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05831111 |
| Placebo | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05831111 |
| mRNA-1189 | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05831111 |
| mRNA-1195.2 | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05831111 |
| mRNA-1195.1 | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05831111 |
| mRNA-1195 | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05831111 |
| Placebo | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05831111 |
| mRNA-1189 | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05831111 |
| mRNA-1195.2 | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05831111 |
| mRNA-1195.1 | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05831111 |
| mRNA-1195 | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05831111 |
| Placebo | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05831111 |
| mRNA-1189 | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05831111 |
| mRNA-1195.2 | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05831111 |
| mRNA-1195.1 | Other | Phase PHASE1 | Epstein-Barr Virus Infection | ACTIVE_NOT_RECRUITING | NCT05831111 |
| mRNA-1283.251 Variant-containing Formulation | Other | Phase PHASE4 | COVID-19 | RECRUITING | NCT07089706 |
| mRNA-1283.251 Variant-containing Formulation | Other | Phase PHASE4 | COVID-19 | RECRUITING | NCT07089706 |
| mRNA-1283.251 Variant-containing Formulation | Other | Phase PHASE4 | COVID-19 | RECRUITING | NCT07089706 |
| mRNA-1083 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06508320 |
| mRNA-1083 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06508320 |
| mRNA-1083 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06508320 |
| Investigational COVID-19 Vaccine Lot B | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| Investigational COVID-19 Vaccine Lot A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| Investigational Influenza Vaccine | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| COVID-19 Vaccine | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| Influenza Vaccine | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| mRNA-1083 Composition 3 Dose B | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| mRNA-1083 Composition 3 Dose A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| mRNA-1083 Composition 2 Dose B | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| mRNA-1083 Composition 2 Dose A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| mRNA-1083 Composition 1 Dose C | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| mRNA-1083 Composition 1 Dose B | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| mRNA-1083 Composition 1 Dose A Lot B | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| mRNA-1083 Composition 1 Dose A Lot A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| Investigational COVID-19 Vaccine Lot B | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| Investigational COVID-19 Vaccine Lot A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| Investigational Influenza Vaccine | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| COVID-19 Vaccine | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| Influenza Vaccine | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| mRNA-1083 Composition 3 Dose B | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| mRNA-1083 Composition 3 Dose A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| mRNA-1083 Composition 2 Dose B | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| mRNA-1083 Composition 2 Dose A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| mRNA-1083 Composition 1 Dose C | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| mRNA-1083 Composition 1 Dose B | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| mRNA-1083 Composition 1 Dose A Lot B | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| mRNA-1083 Composition 1 Dose A Lot A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| Investigational COVID-19 Vaccine Lot B | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| Investigational COVID-19 Vaccine Lot A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| Investigational Influenza Vaccine | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| COVID-19 Vaccine | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| Influenza Vaccine | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| mRNA-1083 Composition 3 Dose B | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| mRNA-1083 Composition 3 Dose A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| mRNA-1083 Composition 2 Dose B | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| mRNA-1083 Composition 2 Dose A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| mRNA-1083 Composition 1 Dose C | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| mRNA-1083 Composition 1 Dose B | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| mRNA-1083 Composition 1 Dose A Lot B | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| mRNA-1083 Composition 1 Dose A Lot A | Other | Phase PHASE2 | Influenza | COMPLETED | NCT06864143 |
| mRNA -1215 | Other | Phase PHASE1 | Nipah Virus Infection | COMPLETED | NCT05398796 |
| mRNA -1215 | Other | Phase PHASE1 | Nipah Virus Infection | COMPLETED | NCT05398796 |
| mRNA -1215 | Other | Phase PHASE1 | Nipah Virus Infection | COMPLETED | NCT05398796 |
| Nimenrix | Other | Phase PHASE1 | Respiratory Syncytial Virus | ACTIVE_NOT_RECRUITING | NCT05743881 |
| Placebo | Other | Phase PHASE1 | Respiratory Syncytial Virus | ACTIVE_NOT_RECRUITING | NCT05743881 |
| mRNA-1365 | Other | Phase PHASE1 | Respiratory Syncytial Virus | ACTIVE_NOT_RECRUITING | NCT05743881 |
| mRNA-1345 | Other | Phase PHASE1 | Respiratory Syncytial Virus | ACTIVE_NOT_RECRUITING | NCT05743881 |
| Nimenrix | Other | Phase PHASE1 | Respiratory Syncytial Virus | ACTIVE_NOT_RECRUITING | NCT05743881 |
| Placebo | Other | Phase PHASE1 | Respiratory Syncytial Virus | ACTIVE_NOT_RECRUITING | NCT05743881 |
| mRNA-1365 | Other | Phase PHASE1 | Respiratory Syncytial Virus | ACTIVE_NOT_RECRUITING | NCT05743881 |
| mRNA-1345 | Other | Phase PHASE1 | Respiratory Syncytial Virus | ACTIVE_NOT_RECRUITING | NCT05743881 |
| Nimenrix | Other | Phase PHASE1 | Respiratory Syncytial Virus | ACTIVE_NOT_RECRUITING | NCT05743881 |
| Placebo | Other | Phase PHASE1 | Respiratory Syncytial Virus | ACTIVE_NOT_RECRUITING | NCT05743881 |
| mRNA-1365 | Other | Phase PHASE1 | Respiratory Syncytial Virus | ACTIVE_NOT_RECRUITING | NCT05743881 |
| mRNA-1345 | Other | Phase PHASE1 | Respiratory Syncytial Virus | ACTIVE_NOT_RECRUITING | NCT05743881 |
| mRNA-1045 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT05606965 |
| mRNA-1345 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT05606965 |
| Inactivated Influenza Vaccine | Other | Phase PHASE2 | Influenza | COMPLETED | NCT05606965 |
| Adjuvanted Quadrivalent Influenza Vaccine | Other | Phase PHASE2 | Influenza | COMPLETED | NCT05606965 |
| Egg-based Quadrivalent Influenza Vaccine | Other | Phase PHASE2 | Influenza | COMPLETED | NCT05606965 |
| mRNA-1010 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT05606965 |
| mRNA-1045 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT05606965 |
| mRNA-1345 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT05606965 |
| Inactivated Influenza Vaccine | Other | Phase PHASE2 | Influenza | COMPLETED | NCT05606965 |
| Adjuvanted Quadrivalent Influenza Vaccine | Other | Phase PHASE2 | Influenza | COMPLETED | NCT05606965 |
| Egg-based Quadrivalent Influenza Vaccine | Other | Phase PHASE2 | Influenza | COMPLETED | NCT05606965 |
| mRNA-1010 | Other | Phase PHASE2 | Influenza | COMPLETED | NCT05606965 |
| Placebo | Other | Phase PHASE2 | SARS-CoV-2 | TERMINATED | NCT05584202 |
| mRNA-1273.214 | Other | Phase PHASE2 | SARS-CoV-2 | TERMINATED | NCT05584202 |
| Placebo | Other | Phase PHASE2 | SARS-CoV-2 | TERMINATED | NCT05584202 |
| mRNA-1273.214 | Other | Phase PHASE2 | SARS-CoV-2 | TERMINATED | NCT05584202 |
| Placebo | Other | Phase PHASE2 | SARS-CoV-2 | TERMINATED | NCT05584202 |
| mRNA-1273.214 | Other | Phase PHASE2 | SARS-CoV-2 | TERMINATED | NCT05584202 |
| mRNA-1273.815 | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT05436834 |
| mRNA-1273.214 | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT05436834 |
| mRNA-1273.815 | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT05436834 |
| mRNA-1273.214 | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT05436834 |
| mRNA-1273.815 | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT05436834 |
| mRNA-1273.214 | Other | Phase PHASE3 | SARS-CoV-2 | COMPLETED | NCT05436834 |
| SARS-CoV-2 Vaccine | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT06694389 |
| Licensed Influenza Vaccine | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT06694389 |
| Placebo | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT06694389 |
| mRNA-1083 | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT06694389 |
| SARS-CoV-2 Vaccine | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT06694389 |
| Licensed Influenza Vaccine | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT06694389 |
| Placebo | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT06694389 |
| mRNA-1083 | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT06694389 |
| SARS-CoV-2 Vaccine | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT06694389 |
| Licensed Influenza Vaccine | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT06694389 |
| Placebo | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT06694389 |
| mRNA-1083 | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT06694389 |
| SARS-CoV-2 Vaccine | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT06694389 |
| Licensed Influenza Vaccine | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT06694389 |
| Placebo | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT06694389 |
| mRNA-1083 | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT06694389 |
| Pembrolizumab | Other | Phase PHASE2 | Melanoma | ACTIVE_NOT_RECRUITING | NCT03897881 |
| mRNA-4157 | Other | Phase PHASE2 | Melanoma | ACTIVE_NOT_RECRUITING | NCT03897881 |
| Pembrolizumab | Other | Phase PHASE2 | Melanoma | ACTIVE_NOT_RECRUITING | NCT03897881 |
| mRNA-4157 | Other | Phase PHASE2 | Melanoma | ACTIVE_NOT_RECRUITING | NCT03897881 |
| Pembrolizumab | Other | Phase PHASE2 | Melanoma | ACTIVE_NOT_RECRUITING | NCT03897881 |
| mRNA-4157 | Other | Phase PHASE2 | Melanoma | ACTIVE_NOT_RECRUITING | NCT03897881 |
| Placebo | Other | Phase PHASE1 | Cytomegalovirus | ACTIVE_NOT_RECRUITING | NCT05575492 |
| mRNA-1647 | Other | Phase PHASE1 | Cytomegalovirus | ACTIVE_NOT_RECRUITING | NCT05575492 |
| Placebo | Other | Phase PHASE1 | Cytomegalovirus | ACTIVE_NOT_RECRUITING | NCT05575492 |
| mRNA-1647 | Other | Phase PHASE1 | Cytomegalovirus | ACTIVE_NOT_RECRUITING | NCT05575492 |
| mRNA-3745 | Other | Phase PHASE1 | Glycogen Storage Disease | ACTIVE_NOT_RECRUITING | NCT05095727 |
| mRNA-3745 | Other | Phase PHASE1 | Glycogen Storage Disease | ACTIVE_NOT_RECRUITING | NCT05095727 |
| Placebo | Other | Phase PHASE3 | Cytomegalovirus Infection | TERMINATED | NCT05085366 |
| mRNA-1647 | Other | Phase PHASE3 | Cytomegalovirus Infection | TERMINATED | NCT05085366 |
| Placebo | Other | Phase PHASE3 | Cytomegalovirus Infection | TERMINATED | NCT05085366 |
| mRNA-1647 | Other | Phase PHASE3 | Cytomegalovirus Infection | TERMINATED | NCT05085366 |
| Placebo | Other | Phase PHASE3 | Cytomegalovirus Infection | TERMINATED | NCT05085366 |
| mRNA-1647 | Other | Phase PHASE3 | Cytomegalovirus Infection | TERMINATED | NCT05085366 |
| Placebo | Other | Phase PHASE3 | Cytomegalovirus Infection | TERMINATED | NCT05085366 |
| mRNA-1647 | Other | Phase PHASE3 | Cytomegalovirus Infection | TERMINATED | NCT05085366 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | RECRUITING | NCT06735248 |
| mRNA-1195 | Other | Phase PHASE2 | Multiple Sclerosis | RECRUITING | NCT06735248 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | RECRUITING | NCT06735248 |
| mRNA-1195 | Other | Phase PHASE2 | Multiple Sclerosis | RECRUITING | NCT06735248 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | RECRUITING | NCT06735248 |
| mRNA-1195 | Other | Phase PHASE2 | Multiple Sclerosis | RECRUITING | NCT06735248 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | RECRUITING | NCT06735248 |
| mRNA-1195 | Other | Phase PHASE2 | Multiple Sclerosis | RECRUITING | NCT06735248 |
| COVID-19 Vaccine 2 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| Investigational COVID-19 Vaccine 2 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| mRNA-1083 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| Influenza Vaccine 2 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| Investigational Influenza Vaccine 2 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| COVID-19 Vaccine 1 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| Investigational COVID-19 Vaccine 1 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| Investigational Influenza Vaccine 1 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| mRNA-1083.3 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| mRNA-1083.2 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| mRNA-1083.1 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| Influenza Vaccine 1 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| COVID-19 Vaccine 2 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| Investigational COVID-19 Vaccine 2 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| mRNA-1083 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| Influenza Vaccine 2 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| Investigational Influenza Vaccine 2 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| COVID-19 Vaccine 1 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| Investigational COVID-19 Vaccine 1 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| Investigational Influenza Vaccine 1 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| mRNA-1083.3 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| mRNA-1083.2 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| mRNA-1083.1 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| Influenza Vaccine 1 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| COVID-19 Vaccine 2 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| Investigational COVID-19 Vaccine 2 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| mRNA-1083 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| Influenza Vaccine 2 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| Investigational Influenza Vaccine 2 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| COVID-19 Vaccine 1 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| Investigational COVID-19 Vaccine 1 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| Investigational Influenza Vaccine 1 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| mRNA-1083.3 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| mRNA-1083.2 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| mRNA-1083.1 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| Influenza Vaccine 1 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05827926 |
| mRNA-3705 | Other | Phase PHASE1 | Methylmalonic Acidemia | RECRUITING | NCT05295433 |
| mRNA-3705 | Other | Phase PHASE1 | Methylmalonic Acidemia | RECRUITING | NCT05295433 |
| mRNA-3705 | Other | Phase PHASE1 | Methylmalonic Acidemia | RECRUITING | NCT05295433 |
| mRNA-1273.214 | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT05330975 |
| Afluria® Quadrivalent | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT05330975 |
| mRNA-1345 | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT05330975 |
| Placebo | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT05330975 |
| mRNA-1273.214 | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT05330975 |
| Afluria® Quadrivalent | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT05330975 |
| mRNA-1345 | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT05330975 |
| Placebo | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT05330975 |
| mRNA-1273.214 | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT05330975 |
| Afluria® Quadrivalent | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT05330975 |
| mRNA-1345 | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT05330975 |
| Placebo | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT05330975 |
| mRNA-1273.214 | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT05330975 |
| Afluria® Quadrivalent | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT05330975 |
| mRNA-1345 | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT05330975 |
| Placebo | Other | Phase PHASE3 | Respiratory Syncytial Virus | COMPLETED | NCT05330975 |
| mRNA-4203 | Other | Phase PHASE1 | Cutaneous Melanoma | RECRUITING | NCT06946225 |
| IMA203 | Other | Phase PHASE1 | Cutaneous Melanoma | RECRUITING | NCT06946225 |
| mRNA-4203 | Other | Phase PHASE1 | Cutaneous Melanoma | RECRUITING | NCT06946225 |
| IMA203 | Other | Phase PHASE1 | Cutaneous Melanoma | RECRUITING | NCT06946225 |
| mRNA-4203 | Other | Phase PHASE1 | Cutaneous Melanoma | RECRUITING | NCT06946225 |
| IMA203 | Other | Phase PHASE1 | Cutaneous Melanoma | RECRUITING | NCT06946225 |
| mRNA-4203 | Other | Phase PHASE1 | Cutaneous Melanoma | RECRUITING | NCT06946225 |
| IMA203 | Other | Phase PHASE1 | Cutaneous Melanoma | RECRUITING | NCT06946225 |
| Surgery (RC plus PLND) | Procedure | Phase PHASE1 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT06305767 |
| Enfortumab Vedotin | Other | Phase PHASE1 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT06305767 |
| Placebo | Other | Phase PHASE1 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT06305767 |
| Intismeran autogene | Other | Phase PHASE1 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT06305767 |
| Pembrolizumab | Other | Phase PHASE1 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT06305767 |
| Surgery (RC plus PLND) | Procedure | Phase PHASE1 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT06305767 |
| Enfortumab Vedotin | Other | Phase PHASE1 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT06305767 |
| Placebo | Other | Phase PHASE1 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT06305767 |
| Intismeran autogene | Other | Phase PHASE1 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT06305767 |
| Pembrolizumab | Other | Phase PHASE1 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT06305767 |
| Surgery (RC plus PLND) | Procedure | Phase PHASE1 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT06305767 |
| Enfortumab Vedotin | Other | Phase PHASE1 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT06305767 |
| Placebo | Other | Phase PHASE1 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT06305767 |
| Intismeran autogene | Other | Phase PHASE1 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT06305767 |
| Pembrolizumab | Other | Phase PHASE1 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT06305767 |
| mRNA-0184 | Other | Phase PHASE1 | Healthy Participants | ACTIVE_NOT_RECRUITING | NCT06655870 |
| mRNA-0184 | Other | Phase PHASE1 | Healthy Participants | ACTIVE_NOT_RECRUITING | NCT06655870 |
| mRNA-0184 | Other | Phase PHASE1 | Healthy Participants | ACTIVE_NOT_RECRUITING | NCT06655870 |
| Placebo | Other | Phase PHASE1 | Methylmalonic Acidemia | ACTIVE_NOT_RECRUITING | NCT04899310 |
| mRNA-3705 | Other | Phase PHASE1 | Methylmalonic Acidemia | ACTIVE_NOT_RECRUITING | NCT04899310 |
| Placebo | Other | Phase PHASE1 | Methylmalonic Acidemia | ACTIVE_NOT_RECRUITING | NCT04899310 |
| mRNA-3705 | Other | Phase PHASE1 | Methylmalonic Acidemia | ACTIVE_NOT_RECRUITING | NCT04899310 |
| Placebo | Other | Phase PHASE1 | Methylmalonic Acidemia | ACTIVE_NOT_RECRUITING | NCT04899310 |
| mRNA-3705 | Other | Phase PHASE1 | Methylmalonic Acidemia | ACTIVE_NOT_RECRUITING | NCT04899310 |
| mRNA-3927 | Other | Phase PHASE1 | Propionic Acidemia | RECRUITING | NCT04159103 |
| mRNA-3927 | Other | Phase PHASE1 | Propionic Acidemia | RECRUITING | NCT04159103 |
| mRNA-3927 | Other | Phase PHASE1 | Propionic Acidemia | RECRUITING | NCT04159103 |
| mRNA-1345 | Other | Phase PHASE3 | Respiratory Syncytial Virus | ACTIVE_NOT_RECRUITING | NCT07117487 |
| mRNA-1345 | Other | Phase PHASE3 | Respiratory Syncytial Virus | ACTIVE_NOT_RECRUITING | NCT07117487 |
| mRNA-1345 | Other | Phase PHASE3 | Respiratory Syncytial Virus | ACTIVE_NOT_RECRUITING | NCT07117487 |
| mRNA-1345 | Other | Phase PHASE3 | Respiratory Syncytial Virus | ACTIVE_NOT_RECRUITING | NCT07117487 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04975893 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04975893 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | COMPLETED | NCT04975893 |
| Placebo | Other | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT06634797 |
| mRNA-1273.712 | Other | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT06634797 |
| Placebo | Other | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT06634797 |
| mRNA-1273.712 | Other | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT06634797 |
| Placebo | Other | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT06634797 |
| mRNA-1273.712 | Other | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT06634797 |
| Placebo | Other | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT06634797 |
| mRNA-1273.712 | Other | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT06634797 |
| Nivolumab/Relatlimab | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06880549 |
| mRNA-4106 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06880549 |
| Nivolumab/Relatlimab | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06880549 |
| mRNA-4106 | Other | Phase PHASE1 | Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06880549 |
| Placebo | Other | Phase PHASE2 | Respiratory Syncytial Virus | ACTIVE_NOT_RECRUITING | NCT06143046 |
| mRNA-1345 | Other | Phase PHASE2 | Respiratory Syncytial Virus | ACTIVE_NOT_RECRUITING | NCT06143046 |
| Placebo | Other | Phase PHASE2 | Respiratory Syncytial Virus | ACTIVE_NOT_RECRUITING | NCT06143046 |
| mRNA-1345 | Other | Phase PHASE2 | Respiratory Syncytial Virus | ACTIVE_NOT_RECRUITING | NCT06143046 |
| Placebo | Other | Phase PHASE2 | Respiratory Syncytial Virus | ACTIVE_NOT_RECRUITING | NCT06143046 |
| mRNA-1345 | Other | Phase PHASE2 | Respiratory Syncytial Virus | ACTIVE_NOT_RECRUITING | NCT06143046 |
| Placebo | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-N332GT5 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-CoreG28v2 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-eODGT8 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| Placebo | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-N332GT5 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-CoreG28v2 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-eODGT8 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| Placebo | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-N332GT5 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-CoreG28v2 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| mRNA-1645-eODGT8 | Other | Phase PHASE1 | HIV Infections | RECRUITING | NCT06694753 |
| Placebo | Other | Phase PHASE3 | Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT06592794 |
| mRNA-1403 | Other | Phase PHASE3 | Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT06592794 |
| Placebo | Other | Phase PHASE3 | Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT06592794 |
| mRNA-1403 | Other | Phase PHASE3 | Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT06592794 |
| Placebo | Other | Phase PHASE3 | Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT06592794 |
| mRNA-1403 | Other | Phase PHASE3 | Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT06592794 |
| SoC Treatment | Drug | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03313778 |
| Pembrolizumab | Other | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03313778 |
| mRNA-4157 | Other | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03313778 |
| SoC Treatment | Drug | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03313778 |
| Pembrolizumab | Other | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03313778 |
| mRNA-4157 | Other | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03313778 |
| SoC Treatment | Drug | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03313778 |
| Pembrolizumab | Other | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03313778 |
| mRNA-4157 | Other | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03313778 |
| Placebo | Other | Phase PHASE4 | SARS-CoV-2 | RECRUITING | NCT07266558 |
| mRNA-1283 | Other | Phase PHASE4 | SARS-CoV-2 | RECRUITING | NCT07266558 |
| mRNA-1273 | Other | Phase PHASE4 | SARS-CoV-2 | RECRUITING | NCT07266558 |
| Placebo | Other | Phase PHASE4 | SARS-CoV-2 | RECRUITING | NCT07266558 |
| mRNA-1283 | Other | Phase PHASE4 | SARS-CoV-2 | RECRUITING | NCT07266558 |
| mRNA-1273 | Other | Phase PHASE4 | SARS-CoV-2 | RECRUITING | NCT07266558 |
| Placebo | Other | Phase PHASE4 | SARS-CoV-2 | RECRUITING | NCT07266558 |
| mRNA-1283 | Other | Phase PHASE4 | SARS-CoV-2 | RECRUITING | NCT07266558 |
| mRNA-1273 | Other | Phase PHASE4 | SARS-CoV-2 | RECRUITING | NCT07266558 |
| mRNA-1647 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05397223 |
| FLUAD® | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05397223 |
| mRNA-1345 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05397223 |
| mRNA-1010 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05397223 |
| mRNA-1273 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05397223 |
| mRNA-1647 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05397223 |
| FLUAD® | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05397223 |
| mRNA-1345 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05397223 |
| mRNA-1010 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05397223 |
| mRNA-1273 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05397223 |
| mRNA-1647 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05397223 |
| FLUAD® | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05397223 |
| mRNA-1345 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05397223 |
| mRNA-1010 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05397223 |
| mRNA-1273 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05397223 |
| mRNA-1647 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05397223 |
| FLUAD® | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05397223 |
| mRNA-1345 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05397223 |
| mRNA-1010 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05397223 |
| mRNA-1273 | Other | Phase PHASE1 | SARS-CoV-2 | COMPLETED | NCT05397223 |
| mRNA-1273 (Moderna COVID-19 vaccine) | Other | Phase PHASE4 | COVID-19 | ACTIVE_NOT_RECRUITING | NCT07279766 |
| mRNA-1273 (Moderna COVID-19 vaccine) | Other | Phase PHASE4 | COVID-19 | ACTIVE_NOT_RECRUITING | NCT07279766 |
| mRNA-1273 (Moderna COVID-19 vaccine) | Other | Phase PHASE4 | COVID-19 | ACTIVE_NOT_RECRUITING | NCT07279766 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | RECRUITING | NCT05683457 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | RECRUITING | NCT05683457 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | RECRUITING | NCT05683457 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | RECRUITING | NCT05683457 |
| Placebo | Other | Phase PHASE2 | Cytomegalovirus Infection | RECRUITING | NCT05683457 |
| mRNA-1647 | Other | Phase PHASE2 | Cytomegalovirus Infection | RECRUITING | NCT05683457 |
| mRNA-3927 | Other | Phase PHASE1 | Propionic Acidemia | RECRUITING | NCT05130437 |
| mRNA-3927 | Other | Phase PHASE1 | Propionic Acidemia | RECRUITING | NCT05130437 |
| mRNA-3927 | Other | Phase PHASE1 | Propionic Acidemia | RECRUITING | NCT05130437 |
| mRNA-1189 | Other | Phase PHASE1 | Epstein-Barr Virus | RECRUITING | NCT07478952 |
| mRNA-1189 | Other | Phase PHASE1 | Epstein-Barr Virus | RECRUITING | NCT07478952 |
| mRNA-1273 Variant-containing Formulation | Other | Phase PHASE4 | SARS-CoV-2 | RECRUITING | NCT06585241 |
| mRNA-1273 Variant-containing Formulation | Other | Phase PHASE4 | SARS-CoV-2 | RECRUITING | NCT06585241 |
| mRNA-1273 Variant-containing Formulation | Other | Phase PHASE4 | SARS-CoV-2 | RECRUITING | NCT06585241 |
| mRNA-1273 Variant-containing Formulation | Other | Phase PHASE4 | SARS-CoV-2 | RECRUITING | NCT06585241 |
| Surgery | Procedure | Phase PHASE2 | Carcinoma, Squamous Cell | COMPLETED | NCT06295809 |
| Intismeran autogene | Other | Phase PHASE2 | Carcinoma, Squamous Cell | COMPLETED | NCT06295809 |
| Pembrolizumab | Other | Phase PHASE2 | Carcinoma, Squamous Cell | COMPLETED | NCT06295809 |
| Surgery | Procedure | Phase PHASE2 | Carcinoma, Squamous Cell | COMPLETED | NCT06295809 |
| Intismeran autogene | Other | Phase PHASE2 | Carcinoma, Squamous Cell | COMPLETED | NCT06295809 |
| Pembrolizumab | Other | Phase PHASE2 | Carcinoma, Squamous Cell | COMPLETED | NCT06295809 |
| Surgery | Procedure | Phase PHASE2 | Carcinoma, Squamous Cell | COMPLETED | NCT06295809 |
| Intismeran autogene | Other | Phase PHASE2 | Carcinoma, Squamous Cell | COMPLETED | NCT06295809 |
| Pembrolizumab | Other | Phase PHASE2 | Carcinoma, Squamous Cell | COMPLETED | NCT06295809 |
| Surgery | Procedure | Phase PHASE2 | Carcinoma, Squamous Cell | COMPLETED | NCT06295809 |
| Intismeran autogene | Other | Phase PHASE2 | Carcinoma, Squamous Cell | COMPLETED | NCT06295809 |
| Pembrolizumab | Other | Phase PHASE2 | Carcinoma, Squamous Cell | COMPLETED | NCT06295809 |
| Placebo | Other | Phase PHASE2 | Squamous Non-small Cell Lung Cancer | RECRUITING | NCT07221474 |
| Nab-paclitaxel | Other | Phase PHASE2 | Squamous Non-small Cell Lung Cancer | RECRUITING | NCT07221474 |
| Paclitaxel | Other | Phase PHASE2 | Squamous Non-small Cell Lung Cancer | RECRUITING | NCT07221474 |
| Carboplatin | Other | Phase PHASE2 | Squamous Non-small Cell Lung Cancer | RECRUITING | NCT07221474 |
| Pembrolizumab | Other | Phase PHASE2 | Squamous Non-small Cell Lung Cancer | RECRUITING | NCT07221474 |
| V940 | Other | Phase PHASE2 | Squamous Non-small Cell Lung Cancer | RECRUITING | NCT07221474 |
| Placebo | Other | Phase PHASE3 | Influenza | RECRUITING | NCT07496450 |
| mRNA-1018-H5 | Other | Phase PHASE3 | Influenza | RECRUITING | NCT07496450 |
| Placebo | Other | Phase PHASE3 | Influenza | RECRUITING | NCT07496450 |
| mRNA-1018-H5 | Other | Phase PHASE3 | Influenza | RECRUITING | NCT07496450 |
| Placebo | Other | Phase PHASE3 | Influenza | RECRUITING | NCT07496450 |
| mRNA-1018-H5 | Other | Phase PHASE3 | Influenza | RECRUITING | NCT07496450 |
| mRNA-2808 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | RECRUITING | NCT07116616 |
| mRNA-2808 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | RECRUITING | NCT07116616 |
| mRNA-2808 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | RECRUITING | NCT07116616 |
| Placebo | Other | Phase PHASE1 | Norovirus Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT05992935 |
| mRNA-1405 | Other | Phase PHASE1 | Norovirus Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT05992935 |
| mRNA-1403 | Other | Phase PHASE1 | Norovirus Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT05992935 |
| Placebo | Other | Phase PHASE1 | Norovirus Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT05992935 |
| mRNA-1405 | Other | Phase PHASE1 | Norovirus Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT05992935 |
| mRNA-1403 | Other | Phase PHASE1 | Norovirus Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT05992935 |
| Placebo | Other | Phase PHASE1 | Norovirus Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT05992935 |
| mRNA-1405 | Other | Phase PHASE1 | Norovirus Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT05992935 |
| mRNA-1403 | Other | Phase PHASE1 | Norovirus Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT05992935 |
| Placebo | Other | Phase PHASE1 | Norovirus Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT05992935 |
| mRNA-1405 | Other | Phase PHASE1 | Norovirus Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT05992935 |
| mRNA-1403 | Other | Phase PHASE1 | Norovirus Acute Gastroenteritis | ACTIVE_NOT_RECRUITING | NCT05992935 |
| Nivolumab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT05533697 |
| Ipilimumab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT05533697 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT05533697 |
| mRNA-4359 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT05533697 |
| Nivolumab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT05533697 |
| Ipilimumab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT05533697 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT05533697 |
| mRNA-4359 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT05533697 |
| Nivolumab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT05533697 |
| Ipilimumab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT05533697 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT05533697 |
| mRNA-4359 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT05533697 |
| BCG | Other | Phase PHASE2 | Urinary Bladder Neoplasms | RECRUITING | NCT06833073 |
| Intismeran autogene | Other | Phase PHASE2 | Urinary Bladder Neoplasms | RECRUITING | NCT06833073 |
| BCG | Other | Phase PHASE2 | Urinary Bladder Neoplasms | RECRUITING | NCT06833073 |
| Intismeran autogene | Other | Phase PHASE2 | Urinary Bladder Neoplasms | RECRUITING | NCT06833073 |
| BCG | Other | Phase PHASE2 | Urinary Bladder Neoplasms | RECRUITING | NCT06833073 |
| Intismeran autogene | Other | Phase PHASE2 | Urinary Bladder Neoplasms | RECRUITING | NCT06833073 |
| Placebo | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Intismeran autogene | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Paclitaxel | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Gemcitabine | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Pemetrexed | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Carboplatin | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Cisplatin | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Pembrolizumab | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| Pembrolizumab | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| Intismeran autogene | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07513376 |
| Pembrolizumab coformulated with berahyaluronidase alfa | Other | Phase PHASE3 | Non-small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07513376 |
| Intismeran | Other | Phase PHASE3 | Non-small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07513376 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07513376 |
| Pembrolizumab coformulated with berahyaluronidase alfa | Other | Phase PHASE3 | Non-small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07513376 |
| Intismeran | Other | Phase PHASE3 | Non-small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07513376 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07513376 |
| Pembrolizumab coformulated with berahyaluronidase alfa | Other | Phase PHASE3 | Non-small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07513376 |
| Intismeran | Other | Phase PHASE3 | Non-small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07513376 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07513376 |
| Pembrolizumab coformulated with berahyaluronidase alfa | Other | Phase PHASE3 | Non-small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07513376 |
| Intismeran | Other | Phase PHASE3 | Non-small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07513376 |
| Placebo | Other | Phase PHASE2 | Squamous Non-small Cell Lung Cancer | RECRUITING | NCT07221474 |
| Nab-paclitaxel | Other | Phase PHASE2 | Squamous Non-small Cell Lung Cancer | RECRUITING | NCT07221474 |
| Paclitaxel | Other | Phase PHASE2 | Squamous Non-small Cell Lung Cancer | RECRUITING | NCT07221474 |
| Carboplatin | Other | Phase PHASE2 | Squamous Non-small Cell Lung Cancer | RECRUITING | NCT07221474 |
| Pembrolizumab | Other | Phase PHASE2 | Squamous Non-small Cell Lung Cancer | RECRUITING | NCT07221474 |
| Intismeran Autogene | Other | Phase PHASE2 | Squamous Non-small Cell Lung Cancer | RECRUITING | NCT07221474 |
| Placebo | Other | Phase PHASE2 | Squamous Non-small Cell Lung Cancer | RECRUITING | NCT07221474 |
| Nab-paclitaxel | Other | Phase PHASE2 | Squamous Non-small Cell Lung Cancer | RECRUITING | NCT07221474 |
| Paclitaxel | Other | Phase PHASE2 | Squamous Non-small Cell Lung Cancer | RECRUITING | NCT07221474 |
| Carboplatin | Other | Phase PHASE2 | Squamous Non-small Cell Lung Cancer | RECRUITING | NCT07221474 |
| Pembrolizumab | Other | Phase PHASE2 | Squamous Non-small Cell Lung Cancer | RECRUITING | NCT07221474 |
| Intismeran Autogene | Other | Phase PHASE2 | Squamous Non-small Cell Lung Cancer | RECRUITING | NCT07221474 |
| Placebo | Other | Phase PHASE2 | Squamous Non-small Cell Lung Cancer | RECRUITING | NCT07221474 |
| Nab-paclitaxel | Other | Phase PHASE2 | Squamous Non-small Cell Lung Cancer | RECRUITING | NCT07221474 |
| Paclitaxel | Other | Phase PHASE2 | Squamous Non-small Cell Lung Cancer | RECRUITING | NCT07221474 |
| Carboplatin | Other | Phase PHASE2 | Squamous Non-small Cell Lung Cancer | RECRUITING | NCT07221474 |
| Pembrolizumab | Other | Phase PHASE2 | Squamous Non-small Cell Lung Cancer | RECRUITING | NCT07221474 |
| Intismeran Autogene | Other | Phase PHASE2 | Squamous Non-small Cell Lung Cancer | RECRUITING | NCT07221474 |
| SPIKEVAX JN.1 | Other | Preclinical | SARS-CoV-2 | ACTIVE_NOT_RECRUITING | NCT06333704 |
| SPIKEVAX XBB.1.5 | Other | Preclinical | SARS-CoV-2 | ACTIVE_NOT_RECRUITING | NCT06333704 |
| SPIKEVAX Bivalent BA.4/5 | Other | Preclinical | SARS-CoV-2 | ACTIVE_NOT_RECRUITING | NCT06333704 |
| SPIKEVAX Bivalent BA.1 | Other | Preclinical | SARS-CoV-2 | ACTIVE_NOT_RECRUITING | NCT06333704 |
| SPIKEVAX JN.1 | Other | Preclinical | SARS-CoV-2 | ACTIVE_NOT_RECRUITING | NCT06333704 |
| SPIKEVAX XBB.1.5 | Other | Preclinical | SARS-CoV-2 | ACTIVE_NOT_RECRUITING | NCT06333704 |
| SPIKEVAX Bivalent BA.4/5 | Other | Preclinical | SARS-CoV-2 | ACTIVE_NOT_RECRUITING | NCT06333704 |
| SPIKEVAX Bivalent BA.1 | Other | Preclinical | SARS-CoV-2 | ACTIVE_NOT_RECRUITING | NCT06333704 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| Pembrolizumab | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| Intismeran autogene | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| Pembrolizumab | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| Intismeran autogene | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06077760 |
| Placebo | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Intismeran autogene | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Paclitaxel | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Gemcitabine | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Pemetrexed | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Carboplatin | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Cisplatin | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Pembrolizumab | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Placebo | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Intismeran autogene | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Paclitaxel | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Gemcitabine | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Pemetrexed | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Carboplatin | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Cisplatin | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Pembrolizumab | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | RECRUITING | NCT06623422 |
| Placebo | Other | Phase PHASE4 | SARS-CoV-2 | ACTIVE_NOT_RECRUITING | NCT07266558 |
| mRNA-1283 | Other | Phase PHASE4 | SARS-CoV-2 | ACTIVE_NOT_RECRUITING | NCT07266558 |
| mRNA-1273 | Other | Phase PHASE4 | SARS-CoV-2 | ACTIVE_NOT_RECRUITING | NCT07266558 |
Total products: 1346